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Abstract 
The induction of Type I Interferons (IFNs) is a powerful and rapid innate defense mechanism against viral 
infection, and many viruses have developed elaborate strategies to overcome the antiviral effects of IFN, 
ensuring their survival and replication. Severe acute respiratory syndrome coronavirus (SARS-CoV) is a 
highly pathogenic virus that causes severe lung disease in humans and is associated with high mortality 
rates. SARS-CoV, like all other successful viruses, encode proteins that counteract the innate immune 
response. A number of reports have indicated the papain-like protease (PLpro) domain of SARS-CoV Non-
Structural Protein 3 (NSP3) as a powerful interferon antagonist, by suppressing interferon regulatory 
factor 3 (IRF3) dependent innate antiviral defenses. IRF3 plays a key role in viral-induced type I IFN 
induction pathway. Thus, viruses are well-known to evade the establishment of an antiviral state by 
regulating the activation of IRF3. However, functional studies detailing the PLpro IFN antagonistic 
abilities, are not describe in the context of the full length nsp3 protein, in which it is contained in virus 
infected cells. Nsp3 is the largest replicase gene product in the coronavirus genome, which contains 
several functional domains that are required for coronavirus replication. Establishment of a stable and 
controllable CoV-nsp3 expression system will allow the physiological relevant study of the PLpro 
mediated function of this protein. Here, I described the development of tetracycline-inducible mammalian 
cell lines for stable expression of the full length nsp3 of HCoV-OC43, HCoV-NL63, MERS-CoV, and SARS-
CoV, respectively. Although these cell lines exhibited stable and tight control of nsp3 expression in the 
presence of tetracycline, I observed a variation in CoV’s nsp3 protein expression levels. However, HeLa-
Fit-SCoV-nsp3 and HeLa-Fit-SCoV-nsp3-delPLP stable cell lines expressed SARS-nsp3 and SARS-
nsp3-delPLP robustly and at comparable levels. I found that expression of SARS-CoV nsp3 compromised 
virus-induced expression of IRF-3-dependent antiviral genes and that such ability depended on the PLpro 
domain. In agreement with our previous study examining the effects of the PLpro domain, the inhibitory 
effect was downstream of the IRF-3 kinases while upstream of IRF-3. Overall, my data demonstrates that 
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The induction of Type I Interferons (IFNs) is a powerful and rapid innate defense 
mechanism against viral infection, and many viruses have developed elaborate strategies 
to overcome the antiviral effects of IFN, ensuring their survival and replication. Severe 
acute respiratory syndrome coronavirus (SARS-CoV) is a highly pathogenic virus that 
causes severe lung disease in humans and is associated with high mortality rates. SARS-
CoV, like all other successful viruses, encode proteins that counteract the innate immune 
response. A number of reports have indicated the papain-like protease (PLpro) domain of 
SARS-CoV Non-Structural Protein 3 (NSP3) as a powerful interferon antagonist, by 
suppressing interferon regulatory factor 3 (IRF3) dependent innate antiviral defenses. 
IRF3 plays a key role in viral-induced type I IFN induction pathway. Thus, viruses are 
well-known to evade the establishment of an antiviral state by regulating the activation of 
IRF3. However, functional studies detailing the PLpro IFN antagonistic abilities, are not 
describe in the context of the full length nsp3 protein, in which it is contained in virus 
infected cells. Nsp3 is the largest replicase gene product in the coronavirus genome, 
which contains several functional domains that are required for coronavirus replication. 
Establishment of a stable and controllable CoV-nsp3 expression system will allow the 
physiological relevant study of the PLpro mediated function of this protein. Here, I 
described the development of tetracycline-inducible mammalian cell lines for stable 
expression of the full length nsp3 of HCoV-OC43, HCoV-NL63, MERS-CoV, and 
SARS-CoV, respectively. Although these cell lines exhibited stable and tight control of 
nsp3 expression in the presence of tetracycline, I observed a variation in CoV’s nsp3 
protein expression levels. However, HeLa-Fit-SCoV-nsp3 and HeLa-Fit-SCoV-nsp3-
delPLP stable cell lines expressed SARS-nsp3 and SARS-nsp3-delPLP robustly and at 
comparable levels. I found that expression of SARS-CoV nsp3 compromised virus-
induced expression of IRF-3-dependent antiviral genes and that such ability depended on 
the PLpro domain. In agreement with our previous study examining the effects of the 
PLpro domain, the inhibitory effect was downstream of the IRF-3 kinases while upstream 
of IRF-3. Overall, my data demonstrates that SARS-CoV nsp3 is a bona fide interferon 
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CHAPTER 1.    INTRODUCTION 
 
 
Brief Overview of Coronaviruses 
 
Coronaviruses (CoVs) are the largest RNA viruses known to date, with non-
segmented positive sense ssRNA genomes of up to 27-32 kb in length (1). CoVs belong 
to the family Coronaviridae in the Nidovirales order. The basic genomic organization is 
similar for all coronaviruses, an organization that consists of several genes encoding 
several nonstructural and structural proteins and a set of accessory proteins that are 
unique to each virus species (1, 2). The genomes of several CoVs are illustrated Figure 
1.1.  All CoVs replicate by a similar and unique mechanism, which is associated with the 
synthesis of an extensive 3’-nested set of multiple subgenomic mRNAs for transcription 
during infection (1-3). Historically, CoVs were divided into three distinct groups, based 
on serological analysis, later confirmed by genome sequencing (1, 4, 5).  In 2009, a new 
taxonomic nomenclature was adopted, as such CoVs are now divided into genera (alpha-, 
beta-, and gammacoronaviruses) corresponding to groups 1, 2, and 3 (6). All mammalian 
CoVs, including all bat coronaviruses, SARS-CoV, and MERS-CoV, belong to the first 
and second genera, Alphacoronaviruses and Betacoronaviruses, whereas all avian CoVs 
belong to the Deltacoronaviruses and Gammacoronaviruses genera. However, within the 
Gammacoronavirus genus, there is only one exception, represented by the Beluga whale 
coronavirus SW1 strain, which was identified in this aquatic mammal (7).  Recently, 
three novel CoVs in birds were identified (8). This discovery formed a distinctive genera 
of CoVs and now represents a novel genus, Deltacoronavirus (8, 9) Table 1.1. 
Coronavirus diversity can be attributed to several factors. First, their large genome size, 
coupled with the lack of proof reading in RNA polymerases, leads to a high mutation 
rate. Second, with their unique replication mechanism of random template switching, 
CoVs have a high recombination frequency, thus promoting their remarkable ability to 
jump between species and readily adapt from animal to human hosts (1, 10, 11).  
 
Coronaviruses infect a variety of animal species, including humans, causing 
mostly respiratory and enteric pathologies, and in some infrequent cases hepatic and 
neurologic pathologies (1,5). Infection can be acute or chronic (1, 5). Many of the animal 
coronaviruses, such as infectious bronchitis virus (IBV), porcine epidemic diarrhea virus 
(PEDV) and bovine coronavirus (BCoV), are of economic importance and therefore are 
very valuable to veterinary research. Human coronaviruses (HCoVs) were first isolated in 
the 1960s (1, 12-15).  Initially, there were very few studies examining the role of CoVs in 
humans, most likely because of their lack of substantiated severe disease-forming 
capabilities.  HCoVs 229E and OC43 were the first HCoVs to be identified.  Since the 
late 1960s, they have been recognized as being the causative agent of upper respiratory 
tract infections such as the common cold (1, 12-15). However, as an opportunistic 
pathogen in more susceptible individuals, including infants, the elderly, and the 
immunocompromised, infection can be more severe (16-20).   
 
In late 2002, a previously uncharacterized virus that was associated with the 





Figure 1.1. Genomic organization of coronaviruses. 
 
The structures of four coronavirus genomic RNAs are shown.  The SARS-CoV genome 
and the genomes for human coronavirus Netherlands-63 (HCoV-NL63), mouse hepatitis 
virus (MHV) and avian infectious bronchitis virus (IBV) respectively.  5’end consists of a 
cap and a leader sequence (L). Red boxes represent ORFs encoding nonstructural 
proteins; blue boxes represent ORFs encoding structural proteins; yellow boxes 





Table 1.1. Coronavirus classification. 
 
Genus  Species 
Alphacoronavirus  Transmissible Gastroenteritis Virus (TGEV) 
Porcine Epidemic Diarrhea Coronavirus (PEDV) 
Human Coronavirus 229E 
Human Coronavirus NL-63 
Betacoronavirus  Mouse Hepatitis Virus (MHV) 
Human Coronavirus OC43 
Human Coronavirus HKU-1 
Severe Acute Respiratory Syndrome Coronavirus 
(SARS-CoV) 
Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV) 
Deltacoronavirus  Bulbul Coronavirus HKU11 (BuCoV-HKU11) 
Thrush Coronavirus HKU12 (ThCoV-HKU12) 
Munia Coronavirus HKU13 (MuCoV-HKU13) 
Gammacoronavirus  Infectious Bronchitis Virus (IBV) 






and mortality, was isolated from humans in Guangdong, China (5). The rapid spread of 
the disease to over 30 countries in a relatively short period of time represented a major 
public health threat. The disease was named severe acute respiratory syndrome (SARS), 
and the etiological agent was quickly identified as a highly contagious novel coronavirus 
(CoV), designated SARS-CoV (5). The severity of the disease was correlated with 
increasing age, with mortality reaching 50% for patients over 60 (6). SARS-CoV is a 
betacoronavirus whose genomic sequence, although similar to other betacoronaviruses, 
was different enough to make this a member of a new coronavirus subgenera (6).  By the 
end of the SARS-CoV worldwide epidemic, more than 8000 SARS cases and around 800 
deaths due to SARs had been recorded (5).  Serological studies suggested that SARS-
CoV had recently emerged in the human population and that cross-species transmission 
from an animal to human host seemed the most plausible reason for its emergence (21). 
SARS-CoV caused the first epidemic of the 21st century and is the first paradigm of 
serious illness in humans caused by a coronavirus.  The fact that a coronavirus could 
cause severe disease in humans sparked an interest in the scientific community to 
understand SARS-CoV and the new disease. 
 
Subsequently, in 2004 and 2005, two previously unknown HCoVs, NL63 and 
HKU1, were discovered and found to cause mild upper respiratory tract infections 
worldwide (22, 23). Less than ten years after the SARS epidemic, another novel human 
CoV was identified in 2012 to cause clinical pathologies similar to those described in 
SARS disease. Many names have been used to refer to this newly identified CoV; 
however, due to its origin, it was later named Middle East Respiratory Syndrome 
(MERS) CoV (24). In contrast to SARS, MERS progresses to a severe respiratory 
infection much more rapidly. MERS-CoV mostly with an origin in the Middle East has 
spread to 23 countries in Europe, Asia and the United States of America (25, 26).  Similar 
to the scenario of the SARS epidemic, it is suggested that MERS-CoV represents another 
series of interspecies-transmission events in CoVs (25, 26).  To date, the World Health 
Organization (WHO) has reported 1621 confirmed cases of MERS-COV infection 
globally, resulting in 584 deaths (http://www.who.int/csr/don/4-december-2015-mers-
saudi-arabia/en/website).  Although the number of infected people who are confirmed to 
have MERS is less than the number of SARS confirmed cases, the mortality rate resulting 
from MERS is a lot higher than the mortality rate resulting from SARS. Nonetheless, the 
rather large number of global SARS cases, which spread rapidly in a short amount of 
time, highlights the propensity of human CoVs to adapt readily to the human host, 
allowing efficient human-to-human transmission.  Although there have not been any new 
infections reported since 2004, resurgence of SARS or of related viruses from zoonotic 
sources remains a distinct possibility, as exemplified by the recent emergence of another 
highly pathogenic HCoV, MERS-CoV.  Thus far, there are no clinically approved 
vaccines or antiviral therapeutics for any of the HCoV infections. Therefore, 






Coronaviruses as Emerging Pathogens 
 
All through history, infectious diseases have emerged worldwide and 
tremendously affected the well-being of human populations. Many of the emerging 
pathogens that impact or threaten human health have emerged from unknown zoonotic 
reservoirs, creating a unique challenge to the scientific and medical community. There 
have been two known occurrences of emergence of highly pathogenic coronaviruses. 
SARS-CoV crossed the species barrier to cause the first pandemic of the 21st century. 
Evidence suggests that SARS-CoV emerged from bats to infect palm civets, sold live in 
open markets, acting as the intermediate host, facilitating animal-to- human and human-
to-human transmission. Examinations of a range of domestic and wild mammals were 
conducted in Guandong, China, after the outbreak of SARS, and these examinations 
support the hypothesis that marketplace animals may have been the source of the virus 
found in humans (27, 28).  Animal traders working with live animals in these markets 
had high seroprevalence for both the human and animal SARS-CoV, although no prior 
history of disease could be detected (27). Furthermore, there is a significant amount of 
serological data suggesting that SARS-CoV had not previously been endemic in humans 
(21). 
 
Guan et al published evidence establishing that Himalayan palm civets, Chinese 
ferret badgers and raccoon dogs all carried SARS-like viruses that were genetically and 
antigenically related to human SARS-CoV (27).  In particular, it was seen that the viruses 
collected from masked palm civets in the early phase of the epidemic and in 2003 
exhibited deletions in open reading frame 8 (ORF 8), which differed in length from 29 
nucleotides to larger deletions that resulted in the loss of the entire ORF 8 region at the 
late phase of the epidemic in 2004, suggesting two separate animal-to-human 
transmission events (5, 21, 27, 29, 30).  The fact that SARS-CoV was present only in 
market or farmed animals, but not in those from the wild (7), suggests that the palm 
civets and other marketplace animals are unlikely to have been the natural reservoir hosts 
of SARS-CoV, but merely a secondary host bridging the gap between bat SARS-like 
CoV and SARS-CoV. The presence of SARS-CoV was detected in different species of 
horseshoe bats (31, 32). Sequencing of genomes from bat SARS-like CoVs revealed an 
overall nucleotide sequence similarity of 88% to 92% for all bat SARS-like CoVs isolates 
to that of the SARS-CoVs isolated from humans or civets (33).  The bat viruses also lack 
the nucleotide deletion, suggesting that SARS-CoVs and SARS-like CoVs share a 
common ancestor (33). These findings indicate that SARS-CoV or SARS-like CoV may 
still persist in different unknown animal reservoirs in nature and that a SARS epidemic 
may recur in the future.   
 
Bat species have also been implicated as primary reservoirs of MERS-CoV, but 
these species are distinct from those that are suggested to have been involved in the 
emergence of SARS-CoV (34).  Interestingly, in addition to being reported in human 
infections, high seropositivity for MERS-CoV has been reported in dromedary camels 
(35, 36). Furthermore, viral sequences obtained from these dromedary camels were 
almost identical to sequences from two human MERS-CoV cases linked to this farm (37).  
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Other animal species such as sheep, goats, and cows were found to be negative for 
MERS-CoV neutralizing antibodies (38, 39). Thus, it is very likely that dromedary 
camels acquired the virus from bats and that the virus has successively spread between 
animals in the Middle East region, a spread representing another zoonotic event occurring 
among CoVs to humans.  Recently, several reports have demonstrated human-to-human 
transmission of MERS-CoV (37, 40). Contrary to the SARS epidemic that was rapidly 
controlled, MERS-CoV still spreads more than 3 years after its identification, with its 
most recent large outbreak in South Korea (http://www.who.int/csr/don/25-october-2015-
mers-korea/en/). Also, there is evidence that other human CoVs have emerged from bats, 
including HCoV 229E and HCoV NL63 (34, 41-42). These findings and others indicate 
that CoVs persist in bats and that these viruses have the ability to mutate, recombine, and 
cross species barriers to emerge as novel severe disease-causing pathogens, further 
complicating the development of vaccines and antiviral therapeutics.   
 
Currently, there are no-FDA approved vaccines or treatment for SARS or MERS, 
so clinical management of patients infected with these highly pathogenic viruses is 
mostly dependent on supportive treatment and prevention of complications. Efforts to 
develop a vaccine for SARS-CoV have utilized a number of strategies, including 
vaccines based on inactivated whole SARS-CoV (1, 43-46), spike subunits (47-49), 
recombinant viruses expressing SARS-CoV proteins (50-53), DNA plasmids expressing 
SARS-CoV structural proteins (54-55), or virus-like particles (VLPs) (56), which have all 
been tested in vitro and in vivo. Although MERS-CoV vaccination approaches are in the 
initial stages, Song et al demonstrated a recombinant modified vaccinia virus Ankara 
(MVA) expressing the full-length MERS-CoV spike (S) protein (MVA-MERS-S) that 
could induce high MERS-CoV neutralizing antibodies in mice (57). Despite the 
tremendous efforts given to developing a vaccine for highly pathogenic coronaviruses, 
their extensive genetic diversity and high frequency of recombination present challenges 
to developing an effective vaccine. For example, vaccination for animal coronavirus IBV 
is only partially successful due to the recombination of IBV vaccine viruses and virulent 
wild-type strains, resulting in the emergence of antigenic variant viruses that cause 
outbreaks of disease in chickens (1, 58). This has been observed in vaccine strains in the 
field and in a natural outbreak of IBV (1, 58). Furthermore, enhanced disease was 
observed in vaccinated animals that subsequently became naturally infected with feline 
infectious peritonitis virus, suggesting that other coronavirus vaccines might also enhance 
rather than protect from disease (1).  
 
Since the SARS epidemic, several studies have been conducted to identify potent 
antiviral therapeutics for SAR-CoV infection. Attempts have been made to use antiviral 
compounds that target specific viral molecules or pathways important to the viral life 
cycle. Other attempts have been made to use drugs that enhance the immune response or 
provide specific antibodies using passive immunization (1, 59-63). Antiviral drugs that 
can control viral loads, thus regulating tissue damage and inflammation, will be most 
effective for highly pathogenic coronaviruses. However, at present, there are no specific 
antiviral drugs that have been proven effective for any HCoV infection. Within a period 
of ten years, two highly pathogenic novel HCoVs, SARS-CoV and MERS-CoV, emerged 
from zoonotic reservoirs to cause severe acute respiratory distress syndrome (ARDS) in 
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humans and are associated with high mortality rates. Thus, such emergence emphasizes 
the need to further understand the virus and host interactions that regulate disease 
severity and infection outcome. 
 
 
SARS Pathogenesis and Acute Respiratory Distress Syndrome 
 
Among the HCoVs known to date, the pathogenesis of SARS appears to be 
distinguished by a complex mechanism, which seems to consist of direct and indirect 
influences.  Specifically, damage to the lung appears to occur directly from SARS-CoV 
infection and replication in target cells, as well as a subsequent indirect injury to the lung 
mediated by an ill-regulated and aberrant immune response.  Prior to the SARS epidemic, 
HCoV 229E and OC43 were the only two CoVs known to infect humans (1, 5). 
Recognition as pathogens of upper respiratory tract infections, and causing minimum 
mortality, made them less interesting, thus generating minimal concern in identifying the 
determinants that regulate disease outcomes (1, 12-15). The emergence of SARS 
rekindled an interest in CoVs’ molecular and cellular basis of pathogenesis. Furthermore, 
it demonstrated that there may be molecular determinants that account for the dramatic 
differences in pathogenesis between other HCoVs and SARS-CoV. The most recent 
emergence of a novel CoV, MERS CoV, which also causes severe disease in humans, 
illustrates the need to understand the pathogenic mechanisms to disease, as well as the 
development of therapeutics and vaccines for controlling and preventing CoVs that cause 
severe disease in humans.   
 
SARS-CoV infection causes a wide spectrum of disease, varying from “influenza-
like” symptoms, such as malaise, fatigue, and high fevers, to a worsening atypical 
pneumonia (5, 64-69). In addition, gastrointestinal manifestations and diarrhea were 
frequently reported in SARS cases (1, 5, 65-66). Globally, the fatality rate was 
approximately 10%, but approached 50% in people 65 years of age or older and those 
with underlying illness (WHO update49050703). SARS-CoV-induced mortality is mainly 
characterized by progressive respiratory failure, due to a massive inflammatory response 
within the lung (ARDS) and a systemic component with widespread extrapulmonary 
dissemination, resulting in virus shedding in respiratory secretions, stools, urine, and 
possibly even sweat (65, 69-73). Lung-pathology findings in fatal SARS cases were 
dominated by diffuse alveolar damage, epithelial cell proliferation, an increase in 
macrophages and other severe pulmonary appearances (69, 72, 74-75). Interestingly, 
laboratory findings in infected individuals included lymphopenia and neutrophilia (66, 
76-78).   In contrast to the incubation period of other respiratory pathogens, SARS-CoV 
typical incubation period is 4-6 days, yet sometimes as short as 2 days, and peaks at 
around day 10 and subsequently declines (1). Transmission of SARS has appeared to 
occur primarily by direct person-to-person contact, droplet and airborne routes (5).  
Equally important, the virus is shed in the feces and urine, making it plausible that fecal-
oral transmission can occur (65).  
 
For a virus to cause disease, viral attachment proteins must first bind to specific 
receptors and, in some cases, co-receptors on the host cell surface, allowing entry into the 
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cell. Thus, the discovery of virus receptors can provide insight into mechanisms of 
pathogenesis. Studies using pseudotyped retroviral and lentiviral vectors, containing the 
SARS-CoV spike (S), membrane (M), and envelope (E) proteins independently and in 
combination, revealed that the S protein is both indispensable and necessary for virus 
attachment to target cells (79-82). SARS-CoV S protein also induces membrane fusion of 
the viral envelope with host cell membranes, using a mechanism similar to that of class I 
fusion proteins such as human immunodeficiency virus (HIV) gp160, influenza virus 
hemagglutinin (HA), and paramyxovirus F protein (83, 84), a process associated with 
conformational changes of the S protein. The functional receptor for SARS-CoV has 
been shown to be a type I transmembrane metallopeptidase, angiotensin-converting 
enzyme 2 (ACE2) (85).    
 
SARS-CoV spike protein plays an essential role in the pathogenesis of SARS. 
SARS-CoV is believed to have been transmitted from palm civets to humans during an 
interspecies- jumping event. Characterization of human and palm civet receptor usage 
revealed that human SARS-CoV can bind both human and palm civet ACE2 whereas the 
palm civet virus can only bind to palm civet ACE2.  Li et al reported mutations of two 
key residues in the receptor-binding domain of the SARS-CoV S protein, responsible for 
the adaptation of the virus to human hosts (86). In comparison of the spike protein from 
palm civets and humans, molecular analysis of key residues in the receptor-binding 
domain showed an accumulation of mutations over a 2-year period, suggesting that 
changes in the receptor- binding domain of the S protein can alter host cell specificity and 
viral pathogenesis, resulting in pathogenic viruses that cause severe disease in humans 
(28, 87).   
 
The major targets of SARS-CoV infection are alveolar Type II pneumocytes and 
ciliated cells of the airway epithelium (1, 5, 88, 89). ACE2 is expressed in the lungs, 
heart, kidney, and small intestines as well as other tissues (90, 91).  Overall, the receptor 
expression pattern explains the tissue tropism of SARS-CoV for the lung, small intestine 
and the kidney. Still, noteworthy contradictions include the absence of virus in 
endothelial cells, where ACE2 is abundantly expressed, compared to the presence of 
SARS-CoV in colonic epithelium and hepatocytes that lack ACE2 expression (73, 91). 
These inconsistencies suggest that the presence of ACE2 may not be the only 
determining factor for tropism of SARS-CoV. The proteolytic enzyme cathespin L seems 
to play an important role in the interaction of SARS-CoV and ACE2 expressing cells. 
Simmons et al demonstrated that SARS-CoV infection was obstructed by specific 
inhibitors of the pH-sensitive endosomal protease cathepsin L (92).  In spite of high 
expression of ACE2 on endothelial cells, they express low levels of cathespin L, 
suggesting that differences in expression of cathespin L in various cell types may explain 
these inconsistencies in SARS-CoV infection in relation to ACE2 expression patterns 
(91, 92).   
 
DC-SIGN (CD209) and its homolog L-SIGN (also called DC-SIGN-R,CD209L) 
are C-type lectins that recognize high mannose-containing carbohydrate residues, present 
on viral-enveloped glycoproteins. DC-SIGN is abundantly expressed at the surface of 
dendritic cells (DCs) localized in the lymphoid tissues and certain macrophages (93, 94). 
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L-SIGN is mostly expressed on endothelial cells in the liver, as well as those in 
lymph nodes and the lungs (95).  DC-SIGN and L-SIGN function as viral attachment 
factors by enhancing viral entry and facilitating infection of cells that express the cognate 
entry receptor (in-cis). They are also able to capture viruses and transfer viral infections 
to other target cells (in-trans) (96-99). Both have been reported to be additional receptors 
for SARS-CoV, yet cells expressing DC-SIGN or L-SIGN in the absence of ACE2 are 
not susceptible or are only partly susceptible to SARS-CoV infection, suggesting that 
binding to these molecules enhances SARS-CoV infection of ACE2 expressing cells (5, 
92, 100, 101). Several reports demonstrate in-trans transmission of SARS-CoV by 
dendritic cells to susceptible target cells (79,101).  Even though the dendritic cells 
examined were capable of transferring infectious virions via a synapse-like structure, 
permissiveness for SARS-CoV infection has not been shown (79). A similar mechanism 
has been described for HIV, in which HIV-1 travels with its target cells to lymph nodes 
where the virus is transferred to T cells at the immunological synapse (99).  Viral 
exploitation of hijacking these two calcium-dependent lectins subverts the host’s innate 
immune defenses and supports virus survival, an observation that may be relevant to 
SARS pathogenesis.   
 
The main cause of death in SARS patients is the development of ARDS. ARDS is 
the most severe clinical form of acute lung injury (ALI) caused by a mixture of indirect 
or direct processes that injure the lung (102).  ARDS is best characterized by diffuse 
alveolar damage, which is the principle lung pathology observed in fatal SARS cases (69, 
74-77,102). Interestingly, in addition to functioning as SARS-CoV receptor, ACE2 plays 
an essential role in the renin-angiotensin system (RAS), which may contribute to the 
pathogenesis of SARS. The renin-angiotensin system (RAS) plays a central role in the 
regulation of cardiovascular and renal functions by maintaining blood-pressure 
homeostasis and electrolyte balance (103,104). ACE2 is the only human homologue of 
the key regulator of blood-pressure angiotensin-converting enzyme (ACE). ACE is a 
metalloproteinase that converts angiotensin I (Ang I) into the potent vasoconstrictor 
angiotensin II (Ang II), inducing hypertension while also inducing cell proliferation and 
fibrosis (105,106). Contrary to ACE, ACE2 functions as a carboxypeptidase and 
negatively regulates the renin-angiotensin system by processing angiotensin I and 
angiotensin II (Ang II) into Ang-(1-9) and Ang-(1-7) respectively. Ang-(1-7) is known to 
act as a vasodilator, with anti-proliferative and apoptotic functions, as a result, 
antagonizing the actions of Ang II (105,106).  
 
Animal experiments using a murine model of ALI demonstrated that ACE2 
protects mice from severe acute lung injury induced by acid aspiration or sepsis, which 
was facilitated by inactivation of Ang II (107). Furthermore, it was reported that mice 
deficient for ACE show significantly improved disease (107).  Kuba et al reported that 
binding of SARS-CoV S protein to ACE2 considerably reduces the expression of ACE2 
in the lung, resulting in a diminished protective role of ACE2 and subsequently acute 
respiratory failure (108).  In addition, intraperitoneal injection of recombinant SARS-
CoV S protein intensified ALI in mice, and this effect was ACE2 specific (108).   Viral 
determinants of SARS-CoV pathogenesis remain to be elucidated. Interestingly, these 
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observations provide a possible molecular explanation for the acute respiratory distress 
syndrome and lethality associated with severe SARS disease. 
 
 
SARS-CoV Genomic Organization and Expression Strategy 
 
Coronaviruses’ virions are spherical enveloped particles about 100 to 160 nm in 
diameter (1). The association of the large single-stranded positive-sense RNA genome 
and the N phosphoprotein forms the long, helical nucleocapsid, inside the virion (1,5, 6). 
The virion surface is surrounded by one or two types of projecting spikes. All CoVs 
possess the large, petal-shaped spikes, formed by the spike (S) glycoprotein, giving them 
their distinctive crown-like morphology, which can be seen under the electron 
microscope (1,2,5,6). The S glycoprotein mediates binding to host cell receptors and 
membrane fusion whereas the smaller spikes that span the surface of the virion consist of 
the hemagglutinin-esterase (HE) glycoproteins and are only present in some 
Betacoronaviruses, such as HCoV OC43 and Mouse Hepatitis Virus (MHV) 
(1,5,109,110) Figure 1.2. The virion envelope also contains the transmembrane (M) 
glycoprotein, a triple-spanning integral membrane protein, which spans the lipid bilayer 
three times (1,6,113), and a small envelope (E) protein, which is the least abundant viral 
protein present on the virion envelope but has been shown to play a major role in viral 
assembly (1,5,6).   
 
The genomic organization of CoVs is very well conserved among all known 
coronaviruses. The coronavirus genome is a non-segmented positive-stranded, 5’-capped, 
3’-polyadenylated RNA molecule that can function as messenger RNAs (mRNAs) (1). 
Encoded within the 5’ end, approximately two thirds of the polycistronic genome is the 
replicase gene, which consists of two large, overlapping, open reading frames (ORF) 1a 
and 1b that specify the viral nonstructural proteins (nsps). Encoded in the 3’ end, 
approximately one third of the genome is the structural proteins arranged in the order 
hemagglutinin esterase (HE), if present, spike (S), envelope (E), membrane (M) and 
nucleocapsid (N) and internal (I) protein encoded within the N gene for some 
CoVs(1,2,5,6). Interspersed between the structural genes is a series of ORFs, encoding 
group-specific accessory proteins, which differ among CoVs in number, nucleotide 
sequence, and gene order, but are conserved within the same genera (1). Although these 
gene products are dispensable for virus replication, it is suggested that these proteins play 
a role in virus-host interactions or interfere with the host’s innate immune responses (6, 
112-115).  
 
Fourteen functional pen reading frames have been identified in the genome of 
SARS-CoV (4, 116).  Conserved in all CoVs are homologs of proteins encoded by the 
overlapping ORFs 1a and 1b, and by ORFs 2, 4, 5, 6 and 9a (4). Interestingly, neither 
SARS-CoV nor MERS-CoV genomic sequence contains a gene for the HE protein, 
which is present in most Betacoronaviruses (3, 4, 109, 110, 116-117).  Translation of 
ORF1a and ORF1ab into two large precursor polyproteins (pp), pp1a and pp1ab, is 
dependent on a ribosomal frame-shifting signal encoded near the end of ORF1a 





Figure 1.2. Schematic of coronavirus virion structure. 
 
S, spike glycoprotein; HE, hemagglutinin-esterase glycoprotein; M, membrane 






a downstream pseudoknot structure formed by the genomic RNA (5, 119). Encoded 
within the polyproteins are two virally encoded cysteine proteases, the papain-like 
protease (PLpro) and a 3C-like protease (3CLpro), which in some cases is referred to as 
main protease (Mpro). These cysteine proteases are excised by their own proteolytic 
activity and are responsible for further processing the pp1a and pp1ab polyproteins 
(3,118 120). Processing of the two large polyproteins is necessary for the release and 
maturation of 16 nonstructural proteins (nsp1-16) (120). 
 
These nonstructural proteins form a membrane-associated, large multi-subunit 
protein replicase complex, which utilizes a reticulovesicular network of double 
membrane vesicles (DMV), originating from the rearrangements of the endoplasmic 
reticulum (121,122). Along with many unknown cellular factors, this replicase protein 
complex is responsible for the replication of the viral genome from a full-length negative-
stranded template, and the transcription of a nested set of eight subgenomic (sg) mRNAs, 
used for translation of structural and accessory proteins (3,4). It has been suggested that 
the establishment of DMVs is initiated by the recruitment of replicase proteins to host 
membranes, a process facilitated by several transmembrane domain-containing replicase 
products, such as nsp3, nsp4 and nsp6 (122-125). This has also been seen with 
arteriviruses, another family within Nidovirales order (126, 127). This viral replication 
strategy may provide a shielded environment for the protection of viral double-stranded 
RNA intermediates from the host cell’s innate immune-detection sensors.  
 
 
SARS-CoV Multi-Domain Non-Structural Protein 3 (NSP3) 
 
Among the 16 nsps encoded within SARS-CoV replicase polyprotein, special 
attention has been given to nsp3, since it is becoming apparent that protein domains 
within nsp3 may serve roles in pathogenesis that are distinctive from viral replication. 
The SARS-CoV nsp3 protein is the largest nsp in the genome, with 1922 amino acids, 
containing several structural and functional domains (3, 4). Nsp3 of SARS-CoV has been 
well characterized structurally by either X-ray crystallography or NMR. It has been 
estimated that SARS-CoV nsp3 has about 14 domains: UB1, AC, ADRP, SUD-N, SUD-
M, SUD-C, UB2, PL2pro, NAB, G2M, TM1, ZF, TM2, and Y, which may have 3 
structural domains (128).  NMR studies were used to determine the structure of the 
highly conserved N-terminal region of nsp3, exhibiting an ubiquitin-like 1 (UBL1) 
globular fold, followed by an acidic domain (AC domain) rich in glutamic acid (129).  
The UBL1 domain is structurally similar to Ras-binding proteins and interferon-
stimulated gene 15 (ISG15) (128). Although the functional significance of the UBL1 
domain has yet to be experimentally validated, these structural similarities may suggest 
that this domain may be important for regulating the host cell responses, thus promoting 
survival.  Following this is the ADP-ribose-1”-phosphatase (ADRP) domain, also called 
the X domain or macro domain, thought to play a role during SARS life cycle (130). The 
SARS Unique Domain (SUD) follows next and has been considered a domain unique to 
SARS-CoV (4). It has been shown that the SUD domain is made up of three domains, 
named by their location the N-terminal SUD-N, the middle SUD-M and the C-terminal 




Recently a new domain was identified in MHV nsp3.  Interestingly, the authors 
show that this novel domain has close structural homology to the SARS-CoV unique 
domain C (SUD-C), suggesting that the SUD domain may not be unique to only SARS-
CoV (132).   
 
Following the SUD domain are an additional UBL domain (UBL2) and the 
catalytically active PLpro.  Unlike other CoVs that encode two different PLPs, SARS-
CoV encodes only one PLP domain termed PLpro within nsp3, which is essential for 
processing the amino terminal end of the replicase polyprotein at 3 junctions, through the 
recognition of LXGG motif, releasing nsp1-nsp3 mature proteins respectively (133). It is 
well known that when two PLP domains are encoded within the coronavirus replicase 
polyprotein, the PLP2 recognizes the LXGG motif and has similar characteristics to 
SARS-CoV PLpro (134). Several studies have revealed that SARS-CoV PLpro is a 
deubiquitinating (DUB) enzyme and has de-ISGylating activity (134-139).  The host cell 
uses both ubiquitin (Ub) and ISG15 as unique signaling components to promote the 
antiviral innate immune responses during SARS-CoV infection. The fact that the PLpro 
can cleave and disrupt important host cell innate immune elements illustrates the 
multifunctional nature of this protease and suggests that it is an excellent drug target for 
the development of antiviral treatments. Downstream of the PLpro domain are a nucleic 
acid-binding domain (NAB), which may function with RNA chaperone activity, and one 
unfamiliar domain named the marker domain (G2M)(125). Subsequent to the G2M 
domain are two transmembrane domains, a putative metal- binding region (ZN) and the Y 
domain, whose function is unclear (3, 4,125).  
 
Due to the large size of the nsp3 protein, in vitro studies examining the functional 
role of domains contained in nsp3 during SARS-CoV infection have predominantly made 
use of truncated domain constructs. Specifically, it is unclear whether the protein 
domains within nsp3 impact the innate immune responses when expressed in the context 
of the full-length nsp3 protein, which is the case in virus-infected cells. Therefore, an 
enhanced understanding of viral components that are critical for efficient replication and 
negative regulation of the host innate immune responses, ultimately regulating 
pathogenesis and virulence, is essential to understanding SARS pathogenesis. 
 
 
The Effect of Virus Infection on Host Innate Immunity 
 
Virus infection represents an evolutionary arms race between virus and the host. 
This antagonistic relationship leads to the host utilizing its intrinsic defense mechanisms 
in an attempt to restrict and eliminate virus infection. Viruses, in turn, have adapted 
multiple strategies to subvert or even manipulate the host defenses to promote its own 
infection. The host innate immune system is the first line of defense against invading 
pathogens, including viruses. Hosts have to sense viral pathogens and induce immune 
responses for protection. Upon the detection of invading viruses, host cells mount an 
immediate antiviral response. While viral recognition triggers early antiviral immune 
defenses promoting virus elimination, a consequence of this strong, immediate, innate 
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immune response may be an aberrant inflammatory response that could cause severe 
disease in the host.  Understanding virus and host interactions is critical to the prevention 
and treatment of viral diseases. 
 
The host innate immune system is equipped with cellular pattern-recognition 
receptors (PRRs) that recognize conserved viral structural components that are 
recognized as foreign to the host, called pathogen-associated molecular patterns (PAMPs) 
(140). Toll- like receptors (TLRs) were the first PRRs to be identified and remain the best 
studied. TLRs are expressed in many cell types including immune cells, such as 
macrophages and dendritic cells, and are localized on the cell surface or endosomal 
compartments (141, 142). There are 5 TLRs that are key in the detection and control of 
viral infection. TLR3 recognizes dsRNA, a replication intermediate generated during the 
life cycle of many RNA viruses. TLR2 and TLR4 sense viral structural proteins or 
glycoproteins, TLR7 and TLR8 recognize viral ssRNA, and TLR9 senses non-methylated 
viral CpG containing DNA (140-142). Thus, viral attachment to the host cell is sensed by 
external TLRs, while viral invasion is recognized by TLRs localized internally. Although 
no TLR has been directly implicated in the recognition of SARS-CoV, a protective role 
for TLRs adaptor proteins was established in MA15-SARS-CoV infection. Wild-type 
mice infected with MA15-SARS-CoV exhibited transient weight loss, from which they 
recovered after 7 days; however, MyD88-deficient mice lost significantly more weight, 
all of which died by day 6 post infection (143). Most recently, Totura et al demonstrated 
that mice deficient in the TLR3/TLR4 adaptor TRIF are highly susceptible to SARS-CoV 
infection, observing a lung pathology that was similar to those seen in human patients 
with severe SARS disease (144). The TRIF-deficient mice also exhibited increases in 
weight loss, mortality, and higher viral titers (144). Additionally, TLR4 was identified as 
a protective host factor against Betacoronavirus Mouse Hepatitis Virus-1 (MHV-1) in a 
respiratory model of SARS disease (145). These findings highlight the significance of 
TLR3/TLR4 adaptor proteins in mediating a protective antiviral innate immune response 
to highly pathogenic coronavirus infections. TLRs recognize a broad range of PAMPs; 
however, it is noteworthy to mention that PRRs other than TLRs are involved in PAMP 
recognition and in the regulation of the innate immune response.  
 
Retinoic-acid-inducible gene I (RIG-I)-like receptors (RLRs), such as RIG-I and 
MDA5, are also an important class of PRRs that have been shown to recognize conserved 
viral-specific components (146). These PRRs are ubiquitously expressed and are 
localized in the cytosol where they survey the cytoplasm for viral dsRNA (147). 
Although RIG-I and MDA5 both recognize viral RNA, they play differential roles in the 
viruses they sense. The difference in the recognition of RNA viruses by RIG-I and 
MDA5 has been credited to their distinctive preferences for viral RNA ligands.  For RIG-
I, 5′-triphosphate (ppp)-containing RNAs at least 20 base pairs in length—as well as 
short, blunt-ended dsRNAs—have been shown to be the most favorable RIG-I agonist 
(148,149). Although MDA5 ligands are less defined, it has been established that their role 
is more dependent on long and branched-structure dsRNAs (150). Overall, RLR and TLR 
pathways are not redundant, but rather allow the host to combat the virus infection more 
efficiently by sensing viruses through multiple pathways by multiple mechanisms in 




In vitro studies indicate that RIG-I and MDA5 are transcribed during SARS-CoV 
infection; however, it is not known whether SARS-CoV is recognized by these PPRs 
(151). On the contrary, MHV has been shown to be recognized by MDA5 and RIG-I in a 
cell-specific manner (152,153). Considering that MHV and SARS-CoV replicate in the 
cytoplasm where they produce large amounts of dsRNA, it is likely that SARS-CoV 
could be detected by the same sensors. TLRs and RLRs recognize viral PAMPs during 
virus infection to activate the host intracellular defense signaling cascades, resulting in 
the production of Type I Interferons, inflammatory cytokines and chemokines, and the 
subsequent activation of adaptive immunity (146).    
 
One of the most efficient and fundamental events in the induction of the early-
phase antiviral innate immune response is the production of Type I Interferons, named for 
their ability to interfere with viral replication (154). There are two essential events of the 
Type I IFN system: first, the synthesis of Type I IFNs; second, the response to secreted 
Type I IFN’s, Type I IFN-mediated signaling.  Type I IFNs can be classified into two 
principal classes: IFN-β, the immediate early genes expressed by the initial response to 
invading viruses, and IFN-α, the delayed set of genes expressed by a secondary de novo 
protein-synthesis pathway (155).  At the molecular level, the induction of type I IFNs is 
initiated by sensing the invading viral pathogen through the appropriate PRR(s), which 
triggers multiple and distinct intracellular signal transduction. Although the pathways 
may differ initially, they all converge to activate the latent transcription factors such as 
nuclear factor-kappa B and the interferon regulatory factors (IRFs). 
 
The IRF transcription factors are key regulators in the synthesis of type I IFNs. In 
particular, IRF-3 and IRF-7 are vital. IRF-3 is constitutively expressed in most cell types 
and plays a central role in the production of IFN-β (156). In the absence of virus 
infection, this transcriptional factor resides in the cytosol in an inactive state.  Upon virus 
infection, IRF-3 undergoes serine phosphorylation in its C-terminal region by kinases 
 of IRF-3, either 
a homodimer or a heterodimer with IRF-7, then translocates to the nucleus, where it 
recruits the transcriptional co-activators CBP and p300, and binds to its target IFN-β 
promoter along with other transcriptional factors to initiate IFN-β mRNA synthesis (156). 
This initial wave of IFN triggers expression of a highly homologous IRF, IRF-7.  IRF-7 
is expressed constitutively at low levels mainly in immune cells. However, it can be 
strongly induced by type I IFN-mediated signaling, making it an important element in the 
IFN-α/β positive feedback loop, where IFN-α/β enhances its own expression (159). This 
phenomenon occurs in a two-step process where IRF-3 induces the early expression of 
IFN-β and IFN-α. These genes subsequently signal through the IFN-α/β receptor and the 
JAK-STAT pathway to induce IRF-7 expression, which contributes to the amplification 
of the transcriptional response through a second wave of interferon gene expression, 
which includes other IFN-α genes that are not induced by the initial stage of virus 
infection (159). Similar to IRF-3, IRF-7 is located in the cytosol in an inactive form. 
Upon virus infection, kinases TBK1 and IKK  phosphorylate IRF-7 on its serines in its 
C-terminal region, allowing dimerization (157, 158).  The dimeric form of IRF-7, either a 




Once transcribed and translated, secreted IFN-β and IFN-α bind to a cell surface 
heterodimeric receptor complex consisting of alpha/beta interferon receptor (IFNAR) 1 
and IFNAR2 subunits.  IFN-β and IFN-α act in an autocrine/paracrine fashion, and bind 
to its cognate receptor on the surface of the same cell or neighboring cells to induce IFN-
β and IFN-α gene expression and subsequently activate the JAK-STAT pathways (160).  
The signal transducers and activators of transcription 1 (STAT1) and STAT2 proteins are 
transcriptional factors that reside in the cytosol in a latent form, which become 
phosphorylated by members of the Janus kinase (JAK) family, JAK-1 and TYK-2 (160). 
Phosphorylated STAT1 and STAT2 form heterodimers that recruit IRF9 to form the 
interferon-stimulated gene factor 3 (ISGF3) complex.  This heterotrimer complex is 
translocated into the nucleus where it binds to IFN-stimulated response element (ISRE) to 
induce expression of a large number of IFN-stimulated genes (ISGs), resulting in the 
establishment of an antiviral state. IRF-3 and IRF-7 are well known as master regulators 
of Type I IFN responses and are firmly integrated within the TLR/RLR dependent 
pathways of the innate immune response to invading viral pathogens. Since IRF-3 plays 
an essential role in the early induction of antiviral gene expression, many viruses have 
developed various mechanisms to inhibit, either directly or indirectly, the activation of 
IRF-3, thus blocking or limiting IFN production (156,160). It is well known that the 
initial virus-host interactions may significantly impact the course and/or outcome of the 
infection. Therefore, understanding the mechanisms by which viruses regulate the early 
host innate immune responses is critical to the treatment and prevention of emerging 
infectious diseases, such as SARS and MERS. 
 
With respect to the role of the innate immune system in SARS-CoV infection, the 
fact that SARS-CoV replicates increasingly in the respiratory tract during the first ten 
days of the disease raises the assumption that SARS infection may cause deficiencies in 
the host innate immune response (5). The relationship between SARS-CoV and the IFN-
α/β response is puzzling. Interestingly, in-vitro studies of SARS-CoV, contrary to other 
viruses, typically demonstrate that SARS-CoV is a poor inducer of type I IFN (161, 162). 
Furthermore, irregular IFN, Interferon Stimulated Genes (ISGs), and cytokine responses 
were observed in SARS patients compared to healthy individuals, providing evidence that 
SARS may be an innate immune-regulated disease (161,163).   
 
 
Induction of the Antiviral State by Interferon 
 
In mammals the interferon system is essential for survival because it provides an 
early line of defense against viral infection. This system is designed to inhibit viral 
replication and block the spread of virus infection in the host.  In addition to their 
antiviral activities, IFNs also have antiproliferative, antitumor, and immunomodulatory 
activities, all of which have a profound effect on the physiology of the cell (154,164). 
There are three main IFN families: Type I (IFNα/β) and III (IFNλ) IFNs, which are most 
recognized for their antiviral activities, and type II (IFNγ) IFNs, which has antiviral 
activities but is best known for its immunomodulatory effects (164). The production of 
IFNs is regulated by a highly complex and coordinated sequence of signaling events 
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facilitated by PRRs, adaptor proteins, kinases, and transcription factors (165,166).  IFNs 
are synthesized in host cells in response to viral infection, secreted into circulation, bind 
to their cognate receptors, and activate the JAK/STAT pathway to enhance the expression 
of hundreds of different ISGs, leading to the establishment of the antiviral state (165, 
166).   
 
ISGs are a diverse group of more than 300 genes that mediate the biological 
effects of IFNs (1, 164). In addition to their roles as downstream effectors of IFN, a 
subset of ISGs is induced in parallel with IFN by dsRNA, and this subset is thought to 
mediate the primary response to virus infection (1, 154).  Different ISGs inhibit different 
steps of viral life cycles, such as viral entry, un-coating, transcription, translation, 
assembly and egress (165, 166).  This distinctive strategy allows the IFN system to 
coordinate a multifaceted attack on virus replication. Studies of ISGs products’ mode of 
action have led to important findings concerning translational control, RNA stability and 
editing, and protein transport and turnover (1, 164).  Among the several hundreds of ISGs 
transcriptionally regulated by IFN, only a few have been extensively characterized. These 
genes encode the dsRNA-activated protein kinase (PKR), the 2’,5’-oligoadenylate 
synthesases (2′–5′ OAS), ribonuclease L (RNase L), the mxyovirus (Mx), and ISG56. 
The functions of these proteins are known to be essential for the induction of an antiviral 
state by IFN. 
 
PKR is constitutively expressed at low levels but not functional until activated 
(167). PKR is activated by the binding of viral dsRNA generated in virus-infected cells as 
by-products of viral replication or transcription. Binding of dsRNA to the N-terminal 
dsRNA binding motifs (dsRBM) of PKR relieves steric inhibition of the kinase domain; 
PKR dimerizes, autophosphorylates and becomes activated (168). Phosphorylated PKR 
can phosphorylate other proteins, but not other inactive PKR molecules (169). Therefore, 
autocatalytic activation of PKR is prevented.  In addition to activation by viral RNAs, 
RNAs of cellular and synthetic origin such as IFNγ mRNA and poly I:C can activate 
PKR.  It has been demonstrated that PKR binds to a pseudoknot structure, with sufficient 
double-stranded character, in IFNγ gene’s 5’ untranslated region (UTR), which 
subsequently activates PKR to then inhibit translation of the transcript via 
phosphorylation of eukaryotic translation-initiation factor 2α  (eIF-2α) (168).  
Furthermore, two additional ligands, heparin and the PKR activator (PACT)—which is 
the only known protein activator of PKR—have been described to directly activate the 
kinase (1,154, 170).   
 
Active PKR mediates translational control by phosphorylating the eIF-2α, 
resulting in global inhibition of protein synthesis that blocks further viral gene translation 
and full amplification of the viral-induced cellular stress response (1, 164). Therefore, 
activation of PKR causes inhibition of cellular protein synthesis and apoptosis, which is 
one unique strategy for IFN-induced inhibition of viral replication and spread. Besides its 
role as a regulator of protein translation, PKR also plays a role in cellular signaling.  In 
response to stimuli such as poly I:C and TNFα, PKR regulates the activation of NF-ĸB 
through the phosphorylation and degradation of IĸBα (1).  In addition, PKR has been 
suggested as a serine kinase for STAT1, a modification that is required for IFN signaling 
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(1). The biological significance of PKR is further observed by the existence of cellular 
and viral regulators of PKR action.  Because PKR promotes cellular apoptosis, viruses 
encode or induce antiapoptotic proteins such as P58IPK, a cellular protein recruited by 
influenza virus, to keep cells alive during virus replication (1). 
 
The IFN-inducible 2′–5′ OASs are a family of proteins of different molecular 
weights encoded by multiple genes (154). Viral dsRNA can directly activate the OAS 
proteins. Activation of OAS does not involve a known RNA binding domain; however, it 
has been shown that the RNA binding site consists of a groove of positively charged 
amino acids formed from noncontiguous regions of OAS (171). Activated OAS uses ATP 
to synthesize 2’,5’-linked oligomers of adenosine (2’-5’A) molecules, yielding mainly a 
series of short 5′-triphosphorylated triadenylate called 2-5A [ppp5′(A2′p5′)2A] (172-
173). The 2′–5′A system also plays a role in antiproliferative activities such as induction 
of apoptosis, senescence, and differentiation, suggesting that OAS is also activated by 
cellular RNAs in the absence of viral infection (174-176).  
 
The best characterized function of 2′–5′A is activation of the endoribonuclease 
RNase L. The 2’–5’A molecules bind to the inactive monomers of RNase L, triggering its 
dimerization through their kinase-like domains and activation (177).  RNase L functions 
to cleave viral ssRNA with specificity for sites 3′ of UpUp and UpAp sequences, and thus 
leads to degradation of viral RNAs (164).  On the other hand, activated RNase L also 
degrades both cellular mRNA and rRNA in the cytoplasm of the cell, leading to damages 
of the host cell machinery, which is required for viral replication and can result in 
apoptosis. This likely contributes to the antiviral actions of RNase L.  Moreover, RNase 
L also cleaves self mRNAs and produces small RNAs that function to activate the RLRs 
to induce IFN-β, thus perpetuating and amplifying IFN-β production in virus-infected 
cells (164).  
 
The IFN-inducible antiviral protein MX is a key mediator of innate antiviral 
defenses induced in host cells. The MX potent action in early antiviral host defenses was 
identified by studies in genetically defined mouse strains resistant to influenza A viruses. 
These studies revealed that resistance was caused by a single gene, Mx1, localized on 
chromosome 16 (172,178). Subsequently, two human Mx genes were identified and 
shown to encode for proteins called MxA and MxB, respectively (178).  Mx proteins are 
large GTPases in the dynamin superfamily, which self-assemble into horseshoe- and ring-
shaped helices and bind to viral nucleocapids (178,179).  They inhibit viruses by 
interfering with intracellular trafficking and activity of viral polymerases, thus blocking 
an early stage of the replication cycle (164). The subcellular location of Mx proteins to 
some extent appears to contribute to their antiviral effects on a particular virus. These 
proteins can be located in the cytoplasm or in the nucleus.  Nuclear Mx proteins have 
been shown to confer resistance to viruses, such as Influenza A and Thogoto virus, which 
are known to replicate in the host cell nucleus (164,178). Cytoplasmic murine Mx 
proteins inhibit the replication of viruses that replicate in the cytoplasm, such as VSV and 
LaCrosse virus (LACV) (178). In contrast, some human cytoplasmic Mx proteins have a 
wide-range antiviral specificity against different types of viruses, regardless of their 
intracellular replication site. These MxA-sensitive viruses include members of the 
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bunyaviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, togaviruses, 
picornaviruses, reoviruses and hepatitis B virus, a DNA virus with a genomic RNA 
intermediate (178). 
 
ISG56, which encodes for P56, is one of the first interferon (IFN)-inducible genes 
to be discovered and is the most potently induced gene among all ISGs (154).  ISG56 
belongs to the IFIT genes, which are grouped on human chromosome 10 and consist of 4 
members including ISG56, ISG54, ISG60 and ISG58. (180, 181).  Normally most cell 
types express very low constitutive levels of ISG56 in the absence of stimuli. However, 
induction of ISG56 is initiated by many stimuli, such as IFN, dsRNA and many viruses. 
Since ISG56 mRNAs are very abundant in virus-infected cells, they are used extensively 
as read-outs for studying transcriptional regulation of ISGs by IFN, PRRs, and other 
signaling molecules such as IRF-3 (180). The most potent inducer of ISG56 is type I 
IFNs (IFNα/β) and type III IFNs (IFNλs), whereas type II IFN (IFN-γ) is a much weaker 
inducer.  Although novel insights into the functions of the IFIT-encoded proteins 
continuously emerge in the literature, the best described function of ISG56 and ISG54 is 
the inhibition of cellular translation by binding to specific subunits of eukaryotic 
initiation factor 3 (eIF3), presenting a mechanism of cell growth inhibition distinct from 
other ISGs such as PKR and OAS (180, 181). Use of this distinct strategy may possibly 
delay or inhibit virus replication by diminishing the overall cellular metabolism.  
Interestingly, a newly identified function of ISG56 protein product p56 has been reported. 
Direct binding of p56 to Human Papillomavirus (HPV) E1 helicase inhibits E1 helicase 
activity and sequesters the majority of HPV E1 in the cytoplasm, separating it from the 
viral genomes in the nucleus, thus inhibiting viral DNA replication (181-183). 
 
Lastly, many IFN-pathway signaling proteins, such as RIG-I and MDA5, are 
themselves ISGs, thus providing an autocrine loop that augments IFN responses. Similar 
to RLRs, PKR and OAS proteins are classified as PRRs for the viral PAMP, double-
stranded RNA (dsRNA). However, they differ from typical PRRs in that ligand binding 
results in direct activation of their enzymatic activity rather than initiation of a signaling 
cascade (142, 146,184). Therefore, PKR and OAS can function as early sensors to viral 
infection and can also be augmented as a secondary effect of IFN induction through 
TLR/RLR pathways. The importance of ISGs is further proven by the finding that several 
virally encoded antagonists can specifically interrupt the functions of ISGs products, thus 
blocking the establishment of the antiviral state. 
 
IFNs provide a powerful immediate cellular defense against viral infection and 
thus are fundamental for mammals’ survival.  The IFN system is key to the inhibition of 
viral replication and viral spread, which is mediated through the action of specific ISGs. 
The restriction of virus replication by several of these IFN-induced proteins is associated 
with a multitude of physiological changes for the host cell. Although some ISGs function 
to confer a total disruption in the cellular translational machinery to maximize the host 
control of virus infection, IFNs also induce counteractive signals that limit the duration or 
toxicity of IFN-mediated responses to the host, in an attempt to prevent deleterious 
effects and facilitate cell survival in uninfected cells. Most importantly, these responses 
constitute a negative feedback loop to counteract the massive reorganization of cellular 
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metabolism and machinery triggered by IFN. Furthermore, it is important to consider that 
many IFN-induced antiviral proteins in virus-infected cells are directly induced 
independent of IFN (1). This consideration suggests that these powerful coordinated 
protein functions all work in concert to achieve a fully functional antiviral state and to 
maintain host-virus homeostasis, thus exemplifying the importance of the host innate 
immune system during viral infection. 
 
 
Overview of IFN Antagonists 
 
In order to successfully replicate and spread in a host, a virus must circumvent 
multiple cellular intracellular signaling pathways regulating a wide variety of host cell 
functions.  The production of IFNs is an essential mechanism of the host response to viral 
infections. However, a main priority for most invading viral pathogens is the down-
regulation of the IFN system, a powerful first-line host defense against virus infection. 
The strategies that viruses use to counteract the IFN system are plentiful and include the 
inhibition of IFN synthesis, the inhibition of IFN-mediated signaling pathways, and the 
disruption of the action of IFN-induced proteins with antiviral activity (160). Several 
different viruses contain an ever growing number of IFN-antagonistic proteins that target 
almost all components of the IFN system. These IFN antagonists are typically 
multifunctional proteins that are involved in regulating several different functions in 
virus-infected cells. For example, the P proteins of some negative-strand RNA viruses 
like rabies virus are essential components of the viral RNA polymerase but also inhibit 
the induction of IFN-β in virus-infected cells by targeting TBK1, thus disrupting the 
activation of IRF-3 (185). 
 
It is well known that CoVs possess multiple mechanisms by which they evade the 
host innate immune response, and it has been suggested that this immune evasion may 
contribute to severe coronavirus disease, such as SARS (113,114,186,187). The 
observation that SARS-CoV induces low, sometimes undetectable Type I IFNs following 
productive infection in cell culture, and is relatively resistant to the antiviral effects of 
IFN signaling, suggests that the genome may encode antagonists of IFN synthesis and 
signaling (162,188). Described below are a few examples of SARS-CoV proteins that 
directly affect either IFN induction or signaling.   
 
SARS-CoV encodes the largest number of accessory proteins that share no 
homology with accessory proteins from any other HCoV. Although none are essential for 
virus replication in cell culture (189), SARS-CoV ORF3b and ORF6 were shown to 
block IFN induction and IFN signaling (114).  How ORF3b antagonizes 
IFN induction has not been well-defined; however, the mechanism by which ORF6 
antagonizes the IFN signaling arm of innate immunity has been illustrated. ORF6 protein 
disrupts the formation of the nuclear import complex by tethering karyopherin alpha 2 
and karyopherin beta 1 to the membrane. The subsequent retaining of nuclear import 
factors at the membrane leads to a loss of STAT1 transfer into the nucleus in response to 
interferon signaling, thus inhibiting the expression of genes dependent on STAT-1 
activation to establish an antiviral state (113). Furthermore, it has been shown that 
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MERS-CoV is more sensitive to PEG-IFN treatment than SARS-CoV is (190). This 
profound phenotype may be attributed to the lack of a SARS-CoV ORF6 homologue. 
 
The Nucleocapsid (N) protein of SARS-CoV, a structural component of the 
SARS-CoV virion, has been shown to also act as an antagonist of IFN.  Kopecky-
Bromberg et al demonstrated that SARS-CoV N protein was able to inhibit the induction 
of IFN-β promoter gene expression (114). They also showed that in response to Sendai 
virus infection or polyI:C the N protein is able to block an ISRE promoter (114).  This 
finding indicates that the N protein exerts its effects on both IFN induction and IFN-
mediated signaling to downregulate the IFN system. Studies of the first nonstructural 
protein of SARS-CoV nsp1 suggest that this protein utilizes several mechanisms to 
antagonize Type I IFN production and signaling (191-193). Kamitami et al observed that 
in human 293 cells, SARS-CoV infection suppresses IFN-β mRNA accumulation (192). 
Using a two-pronged mechanism, SARS-CoV nsp1 mediates the degradation of host 
mRNAs and inhibits the cellular translational machinery in infected cells (192,193). 
Furthermore, nsp1 inhibits the phosphorylation of STAT1 (192). In addition to SARS-
CoV nsp1, nsp7 and nsp15 have both been shown to act as potential IFN antagonists but 
are not well characterized (194).   
 
 
Regulation of Innate Immunity by the PLpro Domain of Coronaviruses 
 
Viruses encode proteases that can act as multifunctional proteins that not only 
generate their mature proteins, which is an essential step in viral replication, but also can 
play specific roles in the interaction of the virus with the host innate immune response, by 
cleaving or disrupting the function of key host proteins important for antiviral immunity. 
For example, the coxsackievirus B3 (CVB3) 3Cpro cysteine protease cleaves the innate 
immune adaptor MAVS and TRIF as a strategy to disrupt Type I IFN responses (195).  
Furthermore, hepatitis C virus (HCV) serine protease NS3/4A and hepatitis A virus 
3ABC cysteine protease both use similar mechanisms to cleave MAVS, disrupting the 
RLR signaling pathway, thus abolishing mitochondrial targeting of the adaptor protein 
and ultimately suppressing antiviral innate immune responses (196-198). For these 
viruses and many more, the catalytic activity of the viral proteases represents a unique 
viral strategy to inhibit antiviral innate immune responses.  
 
Whereas most CoVs contain two analogous enzymes called PLP1 and PLP2, 
SARS-CoV utilizes one termed PLpro contained within nsp3, to process the amino-
terminal end of the replicase polyprotein (3-5,120). In addition to recognizing its protease 
activities, Sulea et al predicted that the PLpro of SARS-CoV possesses DUB activities 
based on structural similarities with herpesvirus-associated ubiquitin-specific protease 
(HAUSP), a cellular DUB enzyme (199). Thus, SARS-CoV’s predicted ability to 
recognize the C terminus sequence of ubiquitin, which is common to ubiquitin-like 
molecules, has led to the assumption that the Plpro domain may also cleave ubiquitin-like 
molecules such as ISG15. Several studies purified the catalytic domain of PLpro and 
demonstrated that PLpro proficiently removes di-ubiquitin and branched polyubiquitin 
chains, cleaves ubiquitin-AMC substrates, and has deISGylating activity (135,139, 200, 
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201). These studies were the first to characterize the multifunctional nature of coronaviral 
PLPs. Since then, several groups have demonstrated the DUB and deISGylating activities 
of HCoV-NL63, MHV, and most recently MERS-CoV papain-like proteases 
(137,138,202). However, it is unclear if the DUB and deISGylating activities of 
coronaviral PLPs play a role in the viral replication cycle.   
 
Ubiquitination and ISGylation are post-translational modifications that are 
essential for a wide variety of biological processes, including regulating the innate 
immune responses to pathogens (203, 204). It has been shown in a cell culture system 
that expression of ISG15 inhibited the release of HIV-1 virions from infected cells (205), 
diminished alphavirus replication (206) and inhibited Influenza A virus gene expression 
and replication in human cells (207). Furthermore, ISG15-deficient mice are more 
susceptible to several human pathogens, including influenza A and B viruses, 
herpesviruses, Chikungunya virus (CHIKV), vaccinia virus, and Sindbis viruses (208-
213). Several laboratories have highlighted proteases DUB activity-mediated innate 
immune evasion by many virus groups such as arterviruses, picornaviruses, herpesviruses 
and CoVs (186, 214). Ubiquitination and ISGylation are important elements of the host 
antiviral innate immune response, and SARS-CoV PLpro has the ability to negatively 
regulate these fundamental processes, an ability that may contribute to SARS 
pathogenesis.   
 
Several reports have identified coronaviral papain-like protease domains as 
negative regulators of innate immunity, specifically IRF-3-dependent Type I IFN 
responses. Antagonism of the IRF-3-dependent Type I IFN system by coronavirus PLPs 
has been most extensively studied for the SARS-CoV PLpro. In 2007, Devaraj et al were 
the first to report that SARS-CoV PLpro had the ability to inhibit type I IFN production. 
It was shown that SARS-CoV PLpro mediated antagonism of type I IFN production 
functions upstream of IRF-3 activation by interacting with IRF-3 and inhibiting its 
phosphorylation, dimerization, and nuclear translocation. SARS-CoV PLpro was also 
able to inhibit the activation of the IFN-β promoter in HeLa cells stimulated with SeV 
infection or poly(I:C) treatment (186). It was also reported that the inhibition of the IFN 
response was independent of the protease activity and that the PLpro had no inhibitory 
effect on the NF-ĸB pathway (186). Subsequently, Frieman et al demonstrated that the 
PLpro domain inhibits IRF-3-dependent induction of IFN-β (194). However, the 
mechanism by which this occurs is controversial. Frieman et al confirmed that PLpro 
inhibits the phosphorylation of IRF-3; however, in contrast to the study detailed above, 
the authors demonstrated that there is no direct interaction between SARS-CoV PLpro 
and IRF-3 (194).  Mutagenesis of the active site at two different residues, which has been 
shown to abolish catalytic activity, affected the PLpro antagonistic activity, but at varying 
degrees, with some mutants maintaining the IFN antagonist ability, and others losing their 
antagonistic activity. Interestingly, a variation in DUB activity of the mutants was also 
observed, suggesting that the catalytic activity of PLpro may play a role in IFN 
antagonism (165,194). However, HCoV-NL63 PLP2 has been shown to antagonize type I 




Studies detailing the IFN antagonist activity of MHV PLP2 domain have 
demonstrated that PLP2 can deubiquitinate and inactivate IRF-3 to inhibit IFN induction 
(216).  Furthermore, the authors show that wild-type PLP2, but not the mutant PLP2 that 
lacks the DUB activity, can block IFN induction, thus suggesting that the viral DUB 
activity may be required for PLP2-mediated IFN antagonism (216). More recently, Wang 
et al reported that MHV PLP2 antagonizes IRF-3 dependent signaling by targeting 
TBK1, a kinase that induces phosphorylation and dimerization of IRF-3, and the authors 
suggest that this mechanism is dependent on PLP2 DUB activity (202). Later studies 
have also associated the ability of CoV PLPs to inhibit type I IFN induction with their 
ability to antagonize stimulator of interferon genes (STING), a scaffolding molecule 
required for the activation of IRF-3, and this ability is mediated by catalytic-dependent 
and catalytic-independent activities (217, 218).  
 
Remarkably, it was reported that deletion of the UBL domain at the amino 
terminus of SARS-CoV PLpro led to a loss in IFN antagonistic function for both IRF-3 
and NF-ĸB pathways; however, the protease and DUB activity remained intact (194). 
However, the contribution of the UBL domain to the SARS nsp3 IFN antagonism was 
not observed in the study by Clementz et al (215). Instead, when using purified wild-type 
and Ubl mutant proteases, Mielech et al demonstrated that the Ubl domain adjacent to 
PLP2 of MHV altered viral protease activity and stability.  Furthermore, the authors 
found that these mutations resulted in a decrease of virus replication and an obvious 
attenuation of virulence (219). The relationship between the UBL domain present 
alongside the PLP and the protease activity remains elusive. However, it is quite clear 
that the Ubl domain may play a role in the pathogenesis of CoVs, and further studies are 
needed to elucidate the role of coronavirus protease/DUB activity in PLP-mediated 
interferon antagonism.   
 
The underlying mechanisms that lead to the difference in IFN antagonism profiles 
of the PLPs from different CoVs are not clearly understood.  Moreover, it is not clear if 
the catalytic activity of the PLpro is indispensable for functions unrelated to the 
proteolytic processing of the replicase polyprotein. Additionally, the catalytic activity and 
the DUB activity both depend on the same protease active site; therefore, it is difficult to 
study them independently during virus infection. As such, no direct evidence has been 
reported linking DUB activity to the suppression of PLpro-mediated innate immune 
responses in virus-infected cells. It is also important to consider that a mutation of the 
catalytic active site of the PLpro may not affect its complete ability to interact with 
ubiquitin and ISG15 molecules in virus-infected cells; therefore, IRF-3-dependent 
signaling could still be disrupted. Most importantly, the studies detailed above revealed 
that SARS PLpro and other CoV PLP2 domains are Type I IFN antagonists.  
 
Unless specified, the studies described above make use of constructs consisting of 
just the PLpro domain and its transmembrane domain; however, in virus-infected cells, 
we do not know if the PLpro is exposed to execute the IFN-antagonizing function in the 
context of the full-length nsp3 protein. Thus, overexpression of the PLpro domain 
construct may not reveal a complete profile of the PLpro IFN antagonist properties. 
Therefore, examining the functional role of SARS-CoV PLpro should be in the context of 
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the full-length nsp3, which to date has not been done. Therefore, although a wealth of 
knowledge has been gained from these studies, it remains elusive whether the PLpro 
impacts the IRF-3-dependent innate immune responses when expressed in the context of 
the full-length nsp3 protein, which is the case in virus-infected cells.  
 
 
Statement of Purpose 
 
Within the 21st century, two novel human CoVs have emerged: SARS-CoV and 
MERS-CoV, both of which cause a highly pathogenic respiratory disease in the lung and 
are associated with high mortality rates. On the contrary, other previously known HCoVs, 
such as OC43 and NL63, generally cause mild upper respiratory tract infections. The 
emergence of MERS-CoV nearly ten years after the SARS-CoV pandemic demonstrates 
the capacity of highly pathogenic CoVs to continue to spill over from zoonotic reservoirs 
into the human population, with the potential to become pandemics. The emergence of 
both SARS-CoV and MERS-CoV highlights the significance of understanding the 
pathogenesis of Coronaviruses.  Over the past 10 years, much has been learned about 
highly pathogenic CoVs from the investigation of SARS-CoV, which aids in our efforts 
to combat MERS-CoV; however, gaps in our understanding remain. It is well known that 
the initial virus-host interactions may dramatically impact the course and/or outcome of 
the infection. At present, the differences in the molecular and cellular mechanisms for 
how human CoVs interact with the host innate immune system, resulting in less severe or 
fatal outcomes, are poorly understood.  Several reports have shown the papain-like 
protease (PLP) domain of coronaviral nonstructural protein 3 (nsp3) as a potent IFN 
antagonist by suppressing IRF-3-dependent innate antiviral defenses. The goal of this 
dissertation is to understand the mechanism by which the full-length nsp3 protein of 
different human coronaviruses regulates IRF-3-dependent innate immune responses.   
 
 The objective of Chapter 3 is to create an in-vitro system that can be used to 
characterize the function of the full-length nsp3 protein of CoVs on the 
antagonism of the host type I IFN responses. By investigating the function of the 
full-length nsp3, I hope to assess whether the full-length nsp3 protein can 
differentially regulate the IRF-3-dependent host innate immune responses and 
whether there are any differences in this ability among different coronaviruses. 
 
 The objective of Chapter 4 is to determine whether the full-length nsp3 protein is 
a major contributor to HCoVs antagonism of the interferon response and whether 
this ability may be differentially regulated among the different HCoVs, thus 











The Flp-In T-Rex expression system (Invitrogen) was utilized to generate 
isogenic, stable HeLa cell lines exhibiting tetracycline-inducible expression of HcoV-
OC43-nsp3, HcoV-NL63-nsp3, MERS-CoV-nsp3, or wild type or mutant SARS-nsp3 by 
a Saccharomyces cerevisiae-derived Flp recombinase-dependent DNA homologous 
recombination event. Refer to chapter 3 for detailed procedures. Human embryonic 
kidney (HEK) 293FT cells, were grown and maintained in Dulbecco’s modified Eagle 
medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL 





Conventional PCR and Quick-change site directed mutagenesis (Stratagene) 
(using specific primers containing desired mutations) techniques were used to construct 
N-terminal 2×HA-tagged and mutant forms of HCoV-OC43, HCoV-NL63, MERS-CoV, 
and SARS-CoV nsp3 encoding plasmids in the pcDNA5/FRT/TO backbone (Invitrogen). 
The primers and restriction enzymes used for construction and cloning of recombinant 
plasmids are listed in Table 2.1. The following plasmids were kind gifts from the 
indicated contributors; pcDNA3-FLAG TBK1 and pcDNA3-FLAG IKK (from Kate 
Fitzgerald) (158); pIFN-β-luc. and GFP-IRF3-5D (from Rongtuan Lin) (220). The 





Cell lysates were prepared and quantified for protein concentration and subjected 
to immunoprecipitation (IP) and immunoblot analysis as previously described (221, 222). 
However briefly, to confirm expression of proteins equivalent amounts of whole cellular 
extracts were prepared, separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) in a 7.5 % or 10% polyacrylamide gel. After electrophoresis, 
proteins were transferred to a nitrocellulose blotting membrane (Amersham) in transfer 
buffer for 1 hr.  The membrane was blocked by incubation in phosphate-buffered saline 
(PBS) containing 3% dried milk for 1 h.  The following monoclonal (mAb) and 
polyclonal (pAb) antibodies were utilized: rabbit anti-ISG56 pAb (generated by 
immunizing rabbits with a keyhole limpet hemocyanin-coupled peptide spanning amino 
acids 2 to 19 of human ISG56) (221), mouse anti HA mAb (12ca5 hybridoma culture 
supernatant), mouse anti-VSV-IN mAb (NIH), rabbit phosphorylated IRF3 pAB (cell 
signaling), or mouse anti-actin mAb (Sigma) in 3% milk–PBS at a dilution of 1:500, 
1:50, 1:1000, and 1:5000 respectively. These incubations were done at 4°C overnight or 
at room temperature for 1 to 2 hours. After three 5-min washes with PBS, membranes 
were reacted with a peroxidase-conjugated secondary goat anti-rabbit and goat anti-  
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mouse immunoglobulin G pAbs (Southern Biotech) at a dilution of 1:8000 for 1hr at 
room temperature. After two 5 min washes and one 10 wash, protein bands were then 
visualized with the enhanced chemiluminescence (ECL) detection system as 




Sendai Virus (SeV) Infection, and Poly (I-C) Treatment 
 
Where indicated, cells were infected with 100 hemagglutinin units (HAU)/ml of 
SeV (Cantell strain, Charles River Laboratories) for 16 h prior to cell lysis for luciferase 
reporter assay and/or immunoblot analysis as described previously (221-223). For poly 
(I-C) (Sigma) treatment, poly (I-C) (Sigma) was added directly to the culture medium at 
25µg/ml (M-pIC) and loaded onto the cells for the indicated time period. 
 
 
Transfection and IFN-β Luciferase Reporter Gene Assay 
 
Luciferase assays were performed in 48-well plates (Greiner Bio-one) seeded with 
20000 cells per well in triplicates, cells were then un-induced or induced with tetracycline 
2ug/ml for 48hrs before transfection.  Cells were then transfected in triplicate with the 
IFNβ-Luc (IFNB-pGL3) reporter plasmid (80 ng), and pRL-TK (20ng) (internal control 
to normalize the activity of the IFNβ-Luc reporter plasmid transfection efficiency) 
(Promega), using Lipofectamine 3000 transfection reagents, as per the manufacturer’s 
instructions (220). Twenty four hours later, transfected cells were mock-treated, treated 
with poly (I-C) (Sigma) for 10 h, or infected with SeV (Cantell strain, Charles River 
Laboratories) for 16 h before cell lysis.  IFN-β promoter activities were determined by 
assaying for both firefly luciferase and renilla activities. Data were expressed as mean 
relative luciferase activity (luciferase activity divided by renilla luciferase activity) with 
standard deviation from a representative experiment carried out in triplicate. A minimum 




Vesicular Stomatitis Virus Luciferase Reporter Gene Assay 
 
VSV-Luc is a recombinant firefly luciferase-encoding vesicular stomatitis virus, 
in which in infected cells replication can be monitored by assaying for luciferase activity 
(224). The VSV luciferase assay were performed in 24 well plates (Greiner Bio-one) 
seeded with 40,000 cells per well in triplicates, cells were then un-induced or induced 
with tetracycline 2ug/ml for 48hrs.  Where indicated, cells were mock-treated or treated 
with poly (I-C) (GE Health) or transfected with 2µg of HCV RNA replicon (HCV 
genotype 2a strain JFH1-1581) using Lipofectamine 3000 reagents (Invitrogen) per the 
manufacturer’s instructions for 8-10 hrs.  Cells were then infected with rVSV-Luc. at an 
MOI of 0.1 and virus was removed after 1hr.  At 6-8 hours post infection, luminescence 
was measured using Steady-Glo firefly luciferase reagent (Promega) according to the 
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CHAPTER 3.    GENERATION OF STABLE CELL LINES INDUCIBLY 
EXPRESSING HUMAN CORONAVIRUSES (COV) NONSTRUCTURAL 





There are many viruses that cause severe diseases for which there are neither 
vaccines nor effective antiviral therapies. As a result, millions of people lack treatment 
and preventive measures for these virally induced diseases that may lead to fatal 
outcomes. Thus, many viral diseases continue to be a challenging global health issue. 
Severe acute respiratory syndrome (SARS), the first epidemic of the 21st century, was 
caused by a novel human coronavirus (HCoV), referred to as SARS-associated 
coronavirus (SARS-CoV). In humans, SARS outbreak was the first paradigm of serious 
illness caused by a CoV (1, 5). Moreover, the SARS-CoV epidemic serves as an example 
of the quickness of virus spread expedited by air travel, mass transit and increased 
population density nowadays. Unfortunately, there are no approved vaccines or therapies 
for humans to control SARS-CoV, or any of the HCoVs known to date. In order to design 
successful treatment and prevention methods to virally induced diseases, an in-depth 
understanding of viral components and their contribution to viral pathogenesis is 
essential.   
 
Human coronaviruses were initially considered to be agents of the common cold 
and caused little mortality (1, 12-15). HCoV-OC43 and HCoV-229E were the first two 
HCoVs identified. These two are responsible for about 30% of common colds worldwide 
although the molecular basis of disease was not well studied. However, the SARS-CoV 
epidemic of 2003 demonstrated the ability of a novel CoV to quickly to spread globally 
in immunologically naïve human populations, causing over 8000 cases and a ~10 % 
mortality rate in 29 countries (5, 21). Evidence suggests that SARS-CoV most likely 
evolved from viruses circulating within Chinese horseshoe bats, which are believed to be 
the natural animal reservoirs (31-33). The SARS outbreak sparked a keen interest in the 
disease pathogenesis of CoVs and led to an intense search for additional HCoVs that 
could cause severe disease in humans.  Within the following couple of years, HCoV-
NL63 and HCoV-HKU1, two new HCoVs causing mild disease in humans, were 
identified (22, 23).  Most recently, another novel highly pathogenic CoV, which can 
cause severe disease in humans, emerged suddenly in the Middle East region and was 
designated MERS-CoV (24-26). Likewise, MERS-CoV emerged from a zoonotic 
reservoir to infect humans (34-37). To date, there are 6 known HCoVs. There is an 
obvious difference in the severity of the disease outcome among HCoVs.  Four of these 
are endemic in humans and are mainly associated with mild respiratory illnesses whereas 
the other two CoVs present as emerging infections causing a severe respiratory syndrome 
leading to fatality, thus highlighting the capacity of severe disease potential of the CoV 
family (1, 5,12-15, 21, 24-26). Insight into how CoVs regulate the host cell is critical for 
a full understanding of the molecular mechanisms that contribute to the severe disease 




Coronaviruses, a genus belonging to the Coronaviridae family, are positive-strand 
enveloped RNA viruses that can infect a variety of animal hosts, including humans (1, 2, 
5). They have an incredibly large single-stranded genome, the largest of all RNA viruses 
known to date (2). Coronaviruses encode large replicase polyproteins that are processed 
by two virally encoded proteases, i.e., the papain-like protease (PLP) and a 3C-like 
protease (3CLpro), to generate 15 or 16 nonstructural proteins that are involved in viral 
replication (1-6). For these viruses, the PLP is essential for processing the amino-terminal 
end of the replicase polyproteins (1-6, 118, 120). All human coronaviruses, with the 
exception of SARS-CoV and MERS-CoV, contain two PLPs to process the amino-
terminal portion. It is well known that when two PLPs are encoded within the 
coronavirus replicase polyprotein, PLP2 has similar characteristics to SARS-CoV PLpro 
(120, 132). The investigation of the PLP of SARS-CoV has illustrated the multi-
functionality of coronaviral PLPs. Since PLPs are essential for coronaviral replication, 
they are attractive targets for antiviral treatments. The PLP domain is located within the 
largest replicase subunit, nsp3.  Nsp3 is a multi-domain protein, essential in the formation 
of double membrane vesicles (DMV), a hallmark of coronavirus replication (122-125). 
Earlier reports demonstrated that the PLP of nonstructural protein 3 (nsp3), functions not 
only as a viral protease, but also possesses deubiquitinating (DUB) and deISGylating 
activities (134-139, 199, 201), which are suggested to participate in regulation of the host 
innate immune response to viral infection.  
 
Subsequent reports have shown the papain-like protease (PLP) domain of 
coronaviral nonstructural protein 3 (nsp3) as a potent IFN antagonist by suppressing IRF-
3-dependent innate antiviral defenses. Devaraj et al first reported that SARS-CoV PLP 
inhibits IRF3 activation (186), which was corroborated by reports by other groups (194, 
202, 216). Of note, studies investigating the role of the PLpro domain in regulating the 
host innate immune defenses have mainly relied on the use of transient transfection of 
mammalian cell lines with plasmids encoding truncated nsp3 PLP domain constructs. It is 
likely that this is due to the extremely large size of the nsp3 protein, which made it very 
difficult to clone and express in mammalian cells.. Although transient transfection 
provides a faster way of expression of a protein, the efficiency of transfection typically 
decrease with very large plasmids, making it difficult to achieve comparable expression 
of proteins among each experiment. Stable and regulated gene expression is a very useful 
tool to study further and characterize the function of a gene product. Since the 1990’s, 
tetracycline-regulated expression systems have been widely used for inducible protein 
expression in cell culture (225-227). The construction of stable inducible cell culture 
systems may greatly facilitate the analysis of the function of genes and gene products.   
 
More importantly, it has not been shown whether the CoV PLP domain impacts 
IRF-3 signaling when expressed in the context of the full-length nsp3 protein, which may 
lead to a better understanding of the PLP-mediated function of the nsp3 protein in virus-
infected cells. Thus, it is helpful to establish in-vitro cell systems with stable and 
comparable nsp3 expression, for the study of nsp3 interactions with the host innate 
immune responses. Understanding if the nsp3 protein is a bona fide contributor to human 
CoVs antagonism of the host innate immune response, and if this ability may be 
differentially regulated among different HCoVs, will provide insight into essential 
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virulence factors contributing to CoVs disease outcomes and pathogenesis. To understand 
better the functional role of the nsp3 protein of different HCoVs in regulating IRF-3-
dependent innate immune responses, I used an Flp-In-T-Rex expression system 
successfully to create stable cell lines that express, in a tetracycline-regulated fashion, the 




Materials and Methods 
 
 
Construction of CoV-nsp3 Expression Plasmids  
 
Primers specific for the N and C terminal regions of the nsp3 proteins were used 
to construct the plasmid vectors encoding full length nsp3 protein (HCoV-OC43, HCoV-
NL63, MERS-CoV, and SARS-CoV, respectively) and the PLP-deletion mutant nsp3 
protein of SARS-CoV (Table 2.1). Briefly, the N and C terminal fragments of nsp3s were 
amplified by PCR from corresponding nsp3 cDNAs. The cDNA source for HCoV-OC43 
nsp3 was total RNA extracted from monkey kidney epithelial cells (BSC-1) infected with 
HCoV-OC43 (ATCC VR-1558). HCoV-NL63 (Amsterdam I) RNA from B.E.I. 
resources was as the starting material for HCoV-NL63 cDNA and MERS-CoV cDNA 
was kindly provided by Dr. Heinrich Feldmann’s lab at the National Institute of Health 
(NIH) Rocky Mountain Laboratories. The N and C terminal fragments of SARS-CoV 
nsp3 cDNA was amplified from the full-length nsp3 cDNA of SARS-CoV nsp3 (a gift 
from Dr. Marc Wathelet, Lovelace Respiratory Research Institute) (191). The PCR 
products was digested with appropriate restriction enzymes, purified after gel 
electrophoresis, and ligated into pcDNA5/FRT/TO (Invitrogen), in which nsp3 was fused 
to an N-terminal 2XHA epitope tag. Subsequently, the N- and C-fragments were joined 
together to construct the full length nsp3 protein-encoding plasmids, also in the 
pcDNA5/FRT/TO backbone. Constructs were digested with restriction enzymes to verify 
positive recombinant plasmids Figure 3.1. Subsequently, constructs were sequenced to 
verify incorporation and identity of nsp3 cDNAs.   
 
 
Cell Culture and Generation of Stable Cell Lines 
 
HeLa Flp-In T-Rex cells (a gift from Stephen Taylor at University of Machester) 
(228) were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 100 U/mL penicillin G, 100 U/mL streptomycin, and 2 µg/mL Blasticidin.  
The cells were co-transfected with the pOG44 vector, which expresses the Flp 
recombinase under control of the human CMV promoter, and individual CoV nsp3 
encoding plasmids, i.e., pcDNA5/FRT/TO/HA-HCoV-OC43-nsp3, 
pcDNA5/FRT/TO/HA-HCoV-NL63- nsp3, pcDNA5/FRT/TO/HA-MERS-CoV- nsp3, 
pcDNA5/FRT/TO/HA-SCoV- nsp3 and pcDNA5/FRT/TO/HA-SCoV-nsp3-delPLP, 
respectively.  The pcDNA5/FRT/TO-derived expression plasmids contains a FRT site 
linked to the hygromycin resistance gene for Flp recombinase-mediated integration and 
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selection of stable cell lines expressing individual CoV nsp3 protein under control of a 
tetracycline-regulated CMV/TetO2 promoter (225, 229).  The pOG44 and the 
pcDNA5/FRT/TO/HA-CoV-nsp3 expression constructs were co-transfected in a 9:1 ratio 
using Lipofectamine 3000 reagent (Invitrogen) as described by the manufacturer. Two 
days after transfection the cells were trypsinized and transferred to 10-cm dishes. After 
cells had attached, the growth media was replaced with a selection media containing 200 
µg/mL Hygromycin B and 2 µg/mL Blasticidin (Invitrogen).  The selection media was 
changed every 3 to 4 days until colonies emerged and control cells (untransfected HeLa-
Flp In T-Rex cells) were all dead.  Initial experiments were performed using pooled 
Hygromycin B resistant colonies, which by nature of the Flp-In system were isogenic.  In 
selected experiments involving HeLa-Fit-HCoV OC43-nsp3, HeLa-Fit-HCoV NL63-
nsp3, and HeLa-Fit-MERS CoV-nsp3 stable expressing cells were also performed using 
individual Hygromycin B resistant clones. To induce nsp3, cells were exposed to 2 µg/ml 
of tetracycline, harvested at 48hrs post Tet induction and lysed. Western blot analysis 
was performed to demonstrate inducible expression of nsp3.   
 
 
Western Blot Analysis 
 
To confirm expression of nsp3 proteins, equivalent amounts of whole cellular 
extracts were prepared, separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) in a 7.5 % or 10% polyacrylamide gel. After electrophoresis, 
proteins were transferred to a nitrocellulose blotting membrane (Amersham) in transfer 
buffer for 1 hr.  The membrane was blocked by incubation in phosphate-buffered saline 
(PBS) containing 3% dried milk for 1 h. NSP3 were detected via their HA-epitope tags 
with a monoclonal antibody (mAb) against the HA tag (Invivogen) or a mouse anti-HA 
mAb (clone 12ca5 hybridoma culture supernatant) in 3% milk–PBS at a dilution of 
1:2000 and 1:50, respectively. Expression of SARS-CoV nsp3 protein was also 
confirmed by immunoblotting with a rabbit pAb against nsp3 (Rockland). ISG56 was 
detected via rabbit anti-ISG56 pAb (221) in 3% milk–PBS at a dilution of 1:500.  These 
incubations were done at 4°C overnight or at room temperature for 1 to 2 hours. After 
three 5-min washes with PBS, membranes were reacted with a peroxidase-conjugated 
secondary goat anti-mouse or secondary goat anti-rabbit immunoglobulin G pAbs 
(Southern Biotech) at a dilution of 1:8000 for 1 hr at room temperature. After two 5 min 
washes and one 10 wash, protein bands were then visualized with the enhanced 
chemiluminescence (ECL) detection system as recommended by the manufacturer 
(Millipore), followed by exposure to Kodak Biomax film. 
 
 
Sendai Virus (SeV) Infection 
 
Where indicated, cells were infected with 100 hemagglutinin units (HAU)/ml of 









Identification of Recombinant pcDNA5/FRT/TO/HA-CoV Nsp3 Plasmids by 
Restriction Enzyme Analysis 
 
In order to express the full-length nsp3 protein of HCoVs OC43, NL63, MERS-
CoV and SARS-CoV, I first sub-cloned each nsp3 fragment into the multiple cloning 
sites of the mammalian expression plasmid pcDNA5/FRT/TO/HA. The sizes of 
pcDNA5/FRT/TO/HA, and the cDNA fragment of OC43- nsp3, NL63- nsp3, MERS- 
nsp3, SARS- nsp3 and SARS-nsp3-delPLpro are 5.2Kb, 5.7Kb, 4.7Kb, 5.7Kb, 5.8Kb, 
and 4.8Kb, respectively. After the completion of standard molecular biology techniques 
to construct the recombinant plasmids, positive transformants were analyzed by 
restriction digestion of miniprep DNA. Due to the size similarities of the mammalian 
expression vector and CoV-nsp3 cDNA fragments, to identify successful recombinant 
clones, recombinant pcDNA5/FRT/TO/HA-CoV-nsp3 plasmids were digested with 
multiple restriction enzymes to separate the expression vector and CoV-nsp3 fragments.  
 
Nine pcDNA5/FRT/TO/HA-OC43-nsp3 minipreps were digested with BamHI, 
BsrGI, and XhoI.  Fragments of 5.2Kb, 3.6Kb, and 2.1Kb were generated by each 
miniprep, suggesting all nine minipreps were positive clones Figure 3.1A. Eight 
pcDNA5/FRT/TO/HA-NL63-nsp3 plasmids were cleaved with AgeI, ClaI, and XhoI. 
Fragments of 5.2Kb, 2.8Kb, and 1.9Kb were generated by five of the eight minipreps 
Figure 3.1B.  Six pcDNA5/FRT/TO/HA-MERS-nsp3 plasmids were cleaved with AvrII, 
BamHI, and XhoI. Fragments of 5.2Kb, 4.1Kb, and 1.6Kb were generated by four of the 
minipreps Figure 3.1C.  Two restriction enzyme digestion reactions were used to verify 
pcDNA5/FRT/TO/HA-SARS- nsp3 plasmids. Two plasmids were digested with PmeI, 
generating fragments of 5.9Kb and 5.0Kb and EcoRI and SnaBI generating fragments of 
4.2Kb, 3.8Kb and 2.8Kb, suggesting that both were positive clones Figure 3.1D.  
 
To demonstrate the difference in fragment size, three pcDNA5/FRT/TO/HA-
SARS-nsp3-delPLP plasmids along with two pcDNA5/FRT/TO/HA-SARS-nsp3 wt 
mini-prep plasmids, were cleaved with BamHI, NheI and XhoI.  Fragments of 5.2Kb, 
2.3Kb, and 2.5Kb were generated, confirming lane 6 to be a positive mini-prep for 
pcDNA5/FRT/TO/HA-SARS-nsp3-delPLP Figure 3.1E. Restriction enzyme mapping 
showed that the full length of each CoV-nsp3 and deletion mutant of SARS-nsp3 product 
had been successfully cloned into the specified restriction sites in the 
pcDNA5/FRT/TO/HA vector, and the sizes of the recombinant plasmids were consistent 
with expectation. Sequence analysis confirmed the sequence and orientation of the 
inserted CoV-nsp3 cDNAs in the pcDNA5/FRT/TO/HA vector. 
 
 
Transient Expression of CoVs-Nsp3 Recombinant Plasmids 
 
In an effort to establish stable Tet-regulated inducible cell lines, I first determined 





Figure 3.1. Restriction enzyme digestions of recombinant pcDNA5/FRT/TO/HA-
CoV-nsp3 expression plasmids 
 
(A). Lane 1: 1Kb marker, Lane 2-10: pcDNA5/FRT/TO/HA-OC43-nsp3 minipreps, 
cleaved with BamHI, BSRGI, and XhoI, fragments of 5.2Kb, 3.6Kb, and 2.1Kb indicate 
positive clones. (B) Lane 1: 1Kb marker, Lane 2-9: pcDNA5/FRT/TO/HA-NL63-nsp3 
minipreps, cleaved with AgeI, ClaI, and XhoI. Fragments of 5.2Kb, 2.8Kb, and 1.9Kb 
indicate positive clones.  (C) Lane 1: 1Kb marker, Lane 2-7: pcDNA5/FRT/TO/HA-
MERS-nsp3 minipreps, cleaved with AvrII, BamHI, and XhoI. Fragments of 5.2Kb, 
4.1Kb, and 1.6Kb indicate positive clones. (D) Lane 1: 1Kb marker, Lane 2-5: 
pcDNA5/FRT/TO/HA-SARS-nsp3 minipreps, cleaved with PmeI, fragments of 5.9Kb 
and 5.0Kb and ECoRI and SnaBI generating fragments of 4.2Kb, 3.8Kb and 2.8Kb 
indicate positive clones.  (E) Lane 1: 1Kb marker, Lane 2-3: pcDNA5/FRT/TO/HA-
SARS-nsp3 wild-type minipreps, Lane 4-6: pcDNA5/FRT/TO/HA-SARS-nsp3-delPLpro 
minipreps, cleaved with BamHI, NheI and XhoI, fragments of 5.2Kb, 2.3Kb, and 2.5Kb 





mutant nsp3 protein in transiently-transfected cells. The expression plasmid encoding 
viral nsp3 is N-terminally tagged with two copies of HA tag in the pcDNA5/FRT/TO 
backbone (Invitrogen); therefore, each CoV-nsp3 was detected by using an anti-HA 
antibody. After each construct was developed, I assayed for transient expression of the 
CoV-nsp3 protein. HEK293FT cells were transfected with two micrograms of each 
recombinant plasmid DNA, 48 hrs after transfection cells were assayed for expression. 
Using a monoclonal anti-HA antibody Western Blot analysis confirmed that recombinant 
plasmids gave rise to expression of the full-length OC43-nsp3, NL63-nsp3, MERS-nsp3, 
and SARS-nsp3 wt and mutant proteins, respectively Figure 3.2A-3.2E.  The molecular 
weight of each nsp3 proteins are 212 KDa, 173 KDa, 209 KDa, 213 KDa, and 178 KDa 




Establishment Stable Cell Lines Using the Flp-In T-Rex System 
 
A system that allows stringent inducible regulation of gene expression in 
mammalian cells is a valuable tool for the functional characterization of genes.  The most 
widely used inducible protein expression systems are those regulated by tetracycline 
(Tet) and its derivatives.  In 1992, Gossen et al first described a Tet promoter activating 
system for regulating individual genes in mammalian cells (225).  Since then, the 
tetracycline-regulated gene expression system has gained wide acceptance and has been 
proven to work in both cell lines and mouse models; nonetheless, this system has 
undergone several modifications (227, 230-233). The Flp-In-T-Rex system (Invitrogen) 
is designed to generate cell lines that stably express proteins of interest in an isogenic and 
inducible fashion. This unique feature is due to the fact that the gene of interest (GOI) is 
integrated into the chromosome at a specific site, thus eliminating the possible variation 
in expression levels or patterns that may be due to random integration into the 
chromosome. Furthermore, cells can be grown without expression of the protein of 
interest until such time as it is needed. The ability to induce expression by addition of Tet 
to the culture medium has several advantages over either transient transfection or the 
generation of constitutively expressing stable cell lines. Thus, I used the Flp-In-T-Rex 
expression system successfully to generate stable cell lines that express, in a tetracycline-
regulated fashion, the full-length nsp3 protein of HCoVs OC43, NL63, MERS-CoV and 
SARS-CoV, respectively. 
 
The Flp-In T-Rex-293 system cell line, based upon a derivative of human 293 
embryonic kidney fibroblasts, is widely used by investigators. However, owing to their 
physiological properties, in particular their intact innate immune signaling pathways, we 
selected the Flp-In T-Rex-HeLa system based upon HeLa cells.  The generation of the 
HeLa-Flp-In-CoV-nsp3 cell lines requires that the parental cell lines HeLa-Flp-In-T-Rex 
cells (234) are co-transfected with two plasmids, one containing the gene of interest 
expressing the tetracycline repressor, and the other containing an Flp Recombination 
Target (FRT) site. After verifying transient expression of the CoV-nsp3 constructs, each 
clone that expressed the highest level of CoV-nsp3 protein, based on Western blot 





Figure 3.2. Transient expression of recombinant pcDNA5/FRT/TO/HA-CoV-
nsp3 expression plasmids. 
 
Unless noted, HEK293FT cells were transfected with 2 µg of pcDNA5/FRT/TO/HA-
CoV-nsp3 mini-preps. 48 hrs post transfection cell lysates were harvested, and expression 
of each CoV-nsp3 protein was detected using a monoclonal anti-HA antibody, analyzed 
by Western blotting (A) Lane 1: Mock, Lane 2-7:pcDNA5/FRT/TO/HA-OC43-nsp3 (B) 
Lane 1: Mock, Lane 2-9:pcDNA5/FRT/TO/HA-NL63-nsp3 (C) Lane 1: Mock, Lane 2-5: 
pcDNA5/FRT/TO/HA-MERS-nsp3 (D) Lane 1: Mock, Lane 2-3: pcDNA5/FRT/TO/HA-
SARS-nsp3 (E) HEK293FT cells expressing 2.5 µg of DNA Lane 1: Mock, Lane 2: 
pcDNA5/FRT/TO/HA-SARS-nsp3 Lane 3: pcDNA5/FRT/TO/HA-SARS-nsp3-delPLP. 





expression plasmid, into HeLa-Flp-In-T-Rex cells.  Upon integration of the recombinant 
plasmid into the FRT site, the cells were rendered hygromycin resistant, allowing 
selection of the required integrants with hygromycin.   For each cell line, after 2-3 weeks 
of the selection process, the polyclonal population of cells was pooled, expanded and 
using a monoclonal anti-HA antibody screened for tetracycline-regulated expression of 
the nsp3 protein Figure 3.3A-3.3E. Established cell lines were generated and 
characterized independently and designated HeLa-Fit-OC43-nsp3, HeLa-Fit-NL63-nsp3, 
HeLa-Fit-MERS-nsp3, HeLa-Fit-SCoV-nsp3, and HeLa-Fit-SCoV-nsp3-delPLpro, 
respectively.  In addition, it was observed that the overall growth kinetics of each nsp3-
expressing cell line was similar to that of the parental HeLa-Flp-In T-Rex cells, 
indicating that the CoV-nsp3 expression has no demonstrable effect on cell growth (data 
not shown). These observations supports their potential use as a tool to study the function 
of the full-length CoV-nsp3 proteins. 
 
 
Characterization of Human Coronaviruses Full-Length Nsp3 Inducible Cell Lines 
 
Each cell line was analyzed by immunofluorescence (IFA) staining, using an anti-
HA monoclonal antibody, to further examine CoV-nsp3 expression levels. In the absence 
of tetracycline, each cell line exhibited no detectable nsp3 protein.  Upon addition of 
tetracycline, each cell line demonstrated nsp3 expression, suggesting that tetracycline 
exerted a tight control over the expression of CoV-nsp3 (data not shown).  As expected, I 
observed a cytoplasmic localization pattern for each CoV-nsp3 protein (data not shown). 
However, once all cell lines were generated and examined alongside each other, there 
was an obvious difference in the signal intensity and percentage of cells that expressed 
each CoV-nsp3 (data not shown). The percentage of cells expressing SARS-nsp3 was far 
greater in number than was the percentage of cells expressing HCoV-OC43, HCoV-
NL63, and MERS-CoV nsp3 proteins (data not shown).  Although each cell line was 
generated in the same manner, these results suggest that the CoV-nsp3 stable expressing 
cell lines are not expressing at comparable levels. 
 
In an effort to establish stable cell lines with comparable expression, new Tet-
inducible MERS-CoV, HCoV-OC43, and HCoV-NL63-nsp3 stable expressing cell lines 
were produced by selecting and expanding individual clones and pooled populations, as 
indicated previously. Unexpectedly, upon the addition of Tet for the pooled population, 
HeLa-Fit-OC43-nsp3 and HeLa-Fit-NL63-nsp3 stable cells still demonstrated a low 
percentage of cells expressing nsp3 (data not shown). Furthermore, in the presence of 
Tet, stable cells generated from expanding individual clones did not result in an increase 
in HCoV-OC43 and HCoV-NL63 nsp3 expression (data not shown). However, selecting 
individual colonies to generate HeLa-Fit-MERS-nsp3 stable cells revealed promising 
results. Clone 1 of HeLa-Fit-MERS-nsp3 stable cells demonstrated higher expression of 
MERS-nsp3 in the presence of Tet, when compared to the pooled HeLa-Fit-MERS-nsp3 
stable cells (data not shown).  
 
Ideally, regulation of gene expression can be controlled by adding different 





Figure 3.3. Tet-inducible expression of nsp3 in stable cell lines. 
 
Cells were grown for 48 hrs in the absence (Tet-) (lane 1) or presence (Tet+) (lane 2) of 
2µg/ml Tet treatment. Using an anti-HA antibody, the expression of CoV-nsp3 protein 
was analyzed by Western blotting. (A) HeLa-Fit-OC43-nsp3 cells (B) HeLa-Fit-NL63-
nsp3 cells (C) HeLa-Fit-MERS-nsp3 cells (D) HeLa-Fit-SCoV-nsp3 cells (E) HeLa-Fit-






CoV-nsp3 stable cells was not comparable to that of HeLa-Fit-ScoV-nsp3 cells, I 
investigated dose-dependent inducibility of CoV-nsp3 expression between the two cell 
lines. Since Tet-inducible expression of HeLa-Fit-ScoV-nsp3 cells resulted in robust 
expression of SARS-nsp3, to generate similar levels of expression, concentration 
dependency was examined by inducing SARS-nsp3 with different concentrations of Tet 
(0.1-1µg/ml) for 48 hrs. SARS-nsp3 expression levels that were induced at low 
concentrations of Tet (0.2-1µg ug/mL) were still higher than MERS-nsp3 expression 
levels induced at 2µg/ml of Tet, a concentration that has proven to be optimal in the use 
of the Tet system (data not shown). These findings suggest that for the Tet concentration 
range tested, there was not a concentration-dependent decrease in the amount of SARS-
nsp3 protein induced. 
 
The nsp3 protein is not well conserved between coronaviruses (128). Thus, it 
must be considered that the CoV-nsp3 proteins are being degraded or may have different 
turnover rates.  To examine this aspect, I assayed for transient expression of each CoV-
nsp3 protein, using the CoV-nsp3 expression construct used to generate the stable 
expressing cell lines. HEK293T cells were transfected with two micrograms of each 
recombinant plasmid, 48 hrs after transfection cells were assayed for expression of HA-
nsp3. Using a monoclonal anti-HA antibody Western Blot analysis demonstrated that the 
transient CoV-nsp3 protein expression levels were obviously different Figure 3.4A.  At a 
short exposure time, HCoV-OC43, MERS-CoV and SARS-CoV-nsp3 protein expression 
was observed Figure 3.4A.  In contrast, HCoV-NL63-nsp3 protein expression was only 
observed after prolonged exposure of the Western blot Figure 3.4B. Although gene 
expression is controlled at many levels, it is possible that there are differences in the 
CoV-nsp3 mRNA transcript levels. It is also possible that the codons for each CoV nsp3 
differ in their efficiency in expression in human cells. Until comparable expression can 
be demonstrated, HeLa-Fit-OC43-nsp3, HeLa-Fit-NL63-nsp3, and HeLa-Fit-MERS-nsp3 
stable cells will not be utilized further to characterize the role of these CoV nsp3s in 
regulation of the host innate immune response. 
 
Furthermore, comparable expression was not achieved when 293-Fit-T-Rex, a 
derivative of human embryonic kidney 293 cells, was used as the founder line to generate 
SARS-CoV-, MERS-CoV-, HCoV-OC43-, and HCoV-NL63-nsp3 Tet inducible cell 
lines (data not shown).  Thus my subsequent studies were focused on SARS-CoV nsp3. 
Importantly, HeLa-Fit-derived, Tet-regulated stable cells allowed comparable expression 
of WT and delPLP nsp3 of SARS-CoV Figure 3.5. The observation that other CoV-nsp3 
stable cells failed to express nsp3 at levels comparable to SARS-CoV nsp3, suggesting 
that SARS-CoV codon is optimal for expression in human cells. Therefore, we used 
HeLa-Fit-ScoV-nsp3 cells to gain better insight into the role of nsp3 in the regulation of 





The inducible expression of protein of interest in mammalian cells provides an 





Figure 3.4. Transient expression of recombinant pcDNA5/FRT/TO/HA-CoV-
nsp3 expression plasmids used to generate Tet inducible stable cells. 
 
(A) Short exposure of HEK293T cells were transfected with 2 µg of 
pcDNA5/FRT/TO/HA-CoV-nsp3 mini-preps. 48 hrs post transfection cell lysates were 
harvested, and expression of each CoV-nsp3 protein was detected using a monoclonal 
anti-HA antibody, analyzed by Western blotting. Lane 1: Mock, Lane 
2:pcDNA5/FRT/TO/HA-OC43-nsp3, Lane 3: pcDNA5/FRT/TO/HA-NL63-nsp3, Lane 
4: pcDNA5/FRT/TO/HA-MERS-nsp3, Lane 5 pcDNA5/FRT/TO/HA-SARS-nsp3 Mock: 
No transfection. Actin was used as loading control. (B) Long exposure of HEK293T cells 
were transfected with 2 µg of pcDNA5/FRT/TO/HA-CoV-nsp3 mini-preps. 48 hrs post 
transfection cell lysates were harvested, and expression of each CoV-nsp3 protein was 
detected using a monoclonal anti-HA antibody, analyzed by Western blotting. Lane 1: 
Mock, Lane 2:pcDNA5/FRT/TO/HA-OC43-nsp3, Lane 3: pcDNA5/FRT/TO/HA-NL63-
nsp3, Lane 4: pcDNA5/FRT/TO/HA-MERS-nsp3, Lane 5 pcDNA5/FRT/TO/HA-SARS-










Figure 3.5. Tet-inducible expression of WT and delPLP mutant of SARS-CoV 
nsp3 in HeLa-Fit derived cells. 
 
HeLa-Fit-SARS-nsp3 and HeLa-Fit-SARS-nsp3-delPLP stable cells were grown for 48 h 
in the absence (Tet-) (lanes 1) or presence (Tet+) ( lanes 2) of 2 µg/ml of Tet. Using 
mouse anti HA mAb (12CA5 hybridoma culture supernatant) inducible expression of 







system developed by Gossen and Bujard (225) has been widely used to control inducible 
expression of proteins in cultured mammalian cells. Tet inducible systems are divided 
into two classes, the Tet-On system in which gene expression is induced in the presence 
of tetracycline, and the Tet-Off system where expression of a gene is turned off by Tet 
(234).  Although there are two variants of the Tet based system, we decided to use the 
Tet-on system due to its advantage of not exposing the cells to Tet for prolonged periods 
of time under non-inducing conditions. While possessing many unique attributes, the Tet-
regulated gene expression system has undergone many modifications to tighten the 
control of gene expression.  
 
The Flp-In T-Rex system (Invitrogen) uses a genomic FRT site for integration of 
a gene-of-interest (GOI) by FLP recombinase and is based on the Tet-repressor (TetR) 
that inhibits, via two tetracycline operator (tetO) sequences immediately downstream of 
the CMV promoter, expression of the GOI (229). The incorporation of FLP recombinase-
mediated integration into a pre-integrated FRT site is a useful addition to the Tet-
regulated expression system. It is suggested that this will routinely generate highly 
reproducible stable transgenic cell lines in which protein expression is induced and 
comparable across a population of cells. To achieve highly reproducible results, site-
specific integration of one single gene copy is important. Therefore, to elucidate the 
functional role of various CoV-nsp3 proteins on the antagonism of the host antiviral 
innate immune responses, I chose the well-characterized Flp-In-T-Rex expression system 
to generate stable cell lines that express, in a Tet-regulated fashion, the full-length nsp3 
protein of HCoVs OC43, NL63, MERS-CoV and SARS-CoV, respectively. 
 
In the present study, the full-length cDNA of nsp3 from SARS-CoV, MERS-CoV, 
HCoV-OC43, and HCoV-NL63 was cloned into a mammalian expression vector, and 
positive clones were identified by restriction enzyme digestion of mini-preps Figure 
3.1A-3.1E.  Subsequently, Western-blot analysis confirmed that the recombinant 
plasmids enabled expression of the full-length OC43-nsp3, NL63-nsp3, MERS-nsp3, and 
SARS-nsp3 proteins, in transient transfection experiments Figure 3.2A-3.2E.  The Flp-
In-T-Rex stable cell lines were utilized to ensure comparable expression amongst each 
CoV-nsp3 Tet inducible cell line, thus allowing the investigation of CoV-nsp3 effects in 
physiologically relevant conditions. However, my findings suggest that there are 
considerable variations between stable cells expressing different CoV-nsp3 proteins (data 
not shown). In an attempt to understand the underlying reason, I assayed transient 
expression of all four CoV-nsp3 proteins from the CoV-nsp3 expression constructs used 
to generate the stable expressing cells Figure 3.4. It is possible that the mRNA levels of 
each CoV-nsp3 proteins are different, or that the codons of different CoV nsp3s differ in 
their efficiency for expression in human cells. While various approaches were taken to 
enhance the diminished expression of MERS-CoV-, HCoV-OC43-, and HCoV-NL63-
nsp3 proteins, I show in this study that comparable expression of nsp3 among all four 
CoV-nsp3 stable cell lines could not be achieved (data not shown).   
 
A good way to study the function of a viral protein is to see what happens in the 
host cell when the protein is present.  For this, using a cell-culture system that stably 
expresses the viral protein is advantageous. However, research conducted while 
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characterizing CoV-nsp3 stable expressing cell lines demonstrates that the generation of 
stable Tet-inducible cell culture systems that express large viral proteins in mammalian 
cells can be very complex. Ultimately, with these kind of studies, many biological aspects 
must be considered in the development of these cell-culture systems.  One may argue that 
the amount of mRNA transcribed does not necessarily equal the amount of protein 
produced.  However, there are instances in which variations in mRNA levels strongly 
correlate with change in protein levels. It is possible that the expression of CoV-nsp3 
genes is tightly controlled at the levels upstream of translation. Therefore, it would be 
important for this project to measure each CoV-nsp3 gene product.  Quantifying the level 
of mRNA transcripts will indicate at what magnitude each CoV-nsp3 gene is transcribed.  
To visualize variances in the abundance of mRNA transcripts produced by the different 
CoV-nsp3 stable cells or at different times, I could use the RT-qPCR method. In this 
technique, reverse transcription is followed by quantitative PCR.  This will be an 
important way to determine if there are differences in the transcriptional regulation of the 
CoV-nsp3 proteins, thus causing differences in CoV-nsp3 protein production. 
 
Interestingly, Western blot analysis demonstrates that SARS-CoV-nsp3 protein is 
expressed robustly in either stable Figure 3.3D or transient Figure 3.4 lane 5 expression 
settings.  This observation strongly suggests that the SARS-CoV codon is optimal for 
expression in human cells.  Notably, this is not a cell type-specific phenomenon, as 293-
Fit-SARS-nsp3 stable cells also demonstrated robust, inducible expression of SARS-
nsp3.  With adjusting the codon usage within HCoV-OC43-, HCoV-NL63-, and MERS-
CoV- nsp3 genes to the codons most commonly used by human cells, expression of these 
CoV nsp3s may be achieved (235). Several studies have demonstrated that codon 
optimization can strongly enhance protein expression from several of human 
immunodeficiency virus type-1 (HIV-1) genes in human cells (235-236).  Even though 
codon optimization suggests a primary effect on the translation of the protein, it has been 
suggested that codon optimization could also lead to higher levels of mRNA 
accumulation (237).  Therefore, codon optimization is one approach that may be used to 
increase CoV-nsp3 expression levels.  
 
Although, comparable expression of different CoV-nsp3s was not achieved, the 
generation of stable cell lines has many advantages over transient gene expression 
systems, such as a more uniform gene expression within a cell population, the elimination 
of the need for multiple transfections during experiments, and provision of a system for 
long-term experiments (238). The Flp-In T-Rex system enables the targeted insertion of 
exogenous GOI in a site-specific manner in all transfected cells, thus eliminating the 
potential influence of random genomic insertion and ensuring homogenous levels of the 
GOI expression, allowing for comparisons to be made. There has been much success in 
utilizing this system to induce expression of mammalian proteins to investigate factors 
that control cell proliferation and to reproducibly identify target genes of transcription 
factors (239). Our laboratory previously used this system to demonstrate that TRIM56, an 
IFN- and virus-inducible E3 ubiquitin ligase, is a positive regulator of the TLR3 antiviral 
signaling pathway (223).  More recently, we used this system to determine the molecular 
basis of the versatility and specificity of TRIM56's antiviral activities against positive-
strand RNA viruses (240). Moreover, using the Tet-Off version of the Tet-regulated 
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expression system, work from this lab first identified the PLpro of SARS-CoV as a potent 
IFN antagonist, which disrupts IRF-3-dependent IFN induction by interacting with IRF-3, 
and inhibiting its phosphorylation and nuclear translocation (186).  
 
In future studies, to provide a more genetically homogenous and clonal 
population, individual CoV-nsp3 clones allowing higher expression levels may be 
selected through limiting dilution. Moreover, it may be useful to tag CoV-nsp3 with a 
fluorescent marker (e.g., GFP) and sort high expressers by flow cytometry. In conclusion, 
I have generated a tetracycline-inducible gene expression model system in HeLa cells 
that stably express SARS-CoV-nsp3 Figure 3.3D. I have demonstrated that HeLa-Fit-
ScoV-nsp3 cells express SARS-CoV-nsp3 robustly and the expression is comparable to 
that of a mutant nsp3 lacking the PLP domain in the HeLa-Fit-ScoV-nsp3-delPLP cell 
line Figure 3.5. Such inducible cell lines can serve as a valuable in-vitro model system 




CHAPTER 4.    REGULATION OF IRF-3-DEPENDENT INNATE IMMUNE 
SIGNALING PATHWAY BY THE PLPRO DOMAIN OF NONSTRUCTURAL 






The innate immune response constitutes the first line of defense upon viral 
infection. A hallmark of the host innate immune response to invading viral pathogens is 
the rapid induction of type I IFNs (IFNα and IFNβ) (155).  Type I IFNs are potent 
antiviral cytokines that function in an autocrine/paracrine fashion to induce the 
expression of hundreds of IFN-stimulated genes (ISGs) in the host early after virus 
exposure, thereby establishing an antiviral state that inhibits viral replication and viral 
spread (147,154-155). Because of these essential antiviral properties, type I IFNs are 
considered master regulators of antiviral immunity. In addition to direct inhibition of 
viral replication and spread, another level of IFN action is to shape the adaptive and 
acquired immune responses.  The induction of type I IFNs begins by cellular pattern-
recognition receptors (PRRs) detection of viral molecular signatures called pathogen-
associated molecular patterns (PAMPs) (241).  Toll-like receptors (TLRs) and retinoic-
acid-inducible gene I (RIG-I)-like receptors (RLRs) are two important classes of PRRs 
that have been shown to be involved in the recognition of virus-specific components, 
such as viral surface glycoproteins, intracellular viral proteins, and viral nucleic acids 
(140, 146, 147, 241). Of these, double-stranded RNA (dsRNA) is a prominent viral 
PAMP produced by many RNA viruses as viral replication intermediates, and dsRNA is 
sensed by RIG-I, MDA5, and TLR3 to trigger IFNβ induction (147-150, 241).  
 
Upon engaging viral dsRNAs, RIG-I, MDA5, and TLR3 recruit their cognate 
adaptor proteins MAVS and TRIF respectively, triggering intracellular signaling 
pathways converging on a common TRAF3 adapter complex, which then activates two 
protein kinases TBK1 and IKKε.  These kinases function to activate three distinct 
families of transcription factors, including NF-ĸB, ATF2/c-Jun and IRF-3 
(146,147,154,158).  Assembly of these three transcription factors to the positive 
regulatory domains (PRD) in the IFNβ promoter region induces transcription of the IFNβ 
gene. Of these three transcription factors, IRF-3 is the main regulator in the initial 
induction of IFNβ gene expression induced by viruses.  IRF-3 is a constitutively 
expressed protein that resides in an inactivated state in the cytosol. Upon virus infection, 
activated TBK1 and IKKε directly phosphorylate serine 385 and 386 residues on the 
carboxyl-terminal (c-terminal) region of IRF-3 (242). Furthermore, IRF-3 has been 
shown to undergo virus-induced phosphorylation on a serine-threonine cluster in the C-
terminal region, at amino acids (aa) 396 to 405 (220).  Phosphorylated IRF-3 forms 
homo-dimers, translocates into the nucleus and binds to its target DNA sequence on the 
IFNβ promoter, resulting in the induction of IFN-β gene expression (156-158). 
Consequently, for every host defense, there is a viral offense, and during coevolution 
with their hosts, viruses have evolved and adapted strategies to exploit and modulate the 
cellular IFN responses by encoding viral factors that disrupt host innate immune 
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signaling pathways. The interplay between a virus and its host early in infection largely 
defines disease pathogenesis, thus defining the mechanisms by which viruses modulate 
the host innate immune response, and may provide valuable knowledge that can facilitate 
the development of vaccines and antiviral therapeutics. 
 
SARS-CoV emerged from a zoonotic reservoir in late 2002 to cause the first 
epidemic of the millennium.  First identified in Guangdong Province, China, SARS-CoV 
is the causative agent of the highly contagious viral respiratory disease known as Severe 
Acute Respiratory Syndrome (SARS) (5).  Over a small number of months, this novel 
viral disease became a worldwide threat, spreading to more than two dozen countries 
across 5 continents, infecting 8098 people of all ages, with the elderly more severely 
affected. The World Health Organization (WHO) reported that of those 8098 people who 
became ill, 774 died 
(http://www.who.int/csr/sars/country/table2003_09_23/en/index.html), 68). In humans in 
whom the outcome was fatal, SARS disease was associated with continued uncontrolled 
viral replication and an aberrant inflammatory response in the lung, suggesting that 
SARS-CoV evades and/or modulates host innate antiviral immune responses (68). The 
SARS epidemic has sparked a keen interest among the scientific community to focus its 
attention on the capacity of coronaviruses to counteract or evade the host innate immune 
system and on the need to develop preventive strategies to protect against SARS-CoV 
should the virus re-emerge. In 2012, another highly pathogenic coronavirus emerged to 
cause severe disease in humans, named MERS-CoV, which has a mortality rate of 38% 
(24). To date, there are no FDA-approved antiviral therapeutics or vaccines for any of the 
human coronaviruses. Although there have not been any reported SARS cases in humans 
since 2004, the emergence of MERS-CoV nearly ten years later illustrates that highly 
pathogenic coronaviruses will likely continue to emerge from zoonotic sources to cause 
severe disease in the human population. Furthermore, such emergence highlights the need 
for the discovery of antiviral drugs and/or vaccines against infections caused by 
coronaviruses.   
 
SARS-CoV genome is a large, nonsegmented, positive-stranded, 5’-capped, 3’-
polyadenylated RNA molecule that can function as messenger RNAs (mRNAs) (1). 
Fourteen functional open-reading frames have been identified in the genome of SARS-
CoV (4,116).  As with all coronaviruses, genomic RNA is released in the cell cytoplasm 
after infection and translated into two large replicase polyproteins, called pp1a and pp1ab 
(1, 5, 118). The replicase polyproteins are autoproteolytically cleaved by two viral 
cysteine proteases, the papain-like protease (PLpro) and a 3C-like protease (3CLpro), to 
generate 16 nonstructural proteins (nsp 1 to 16).  The nsps, also referred to as the 
replicase proteins, function to assemble with host cell membranes to generate a complex 
network of double membrane vesicles (DMV), essential for viral RNA replication (3, 
118, 120-122).  For these viruses, the PLpro is essential for processing the amino-
terminal end of the replicase polyproteins at 3 junctions, through the recognition of 
LXGG motif, releasing nsp1-nsp3 mature proteins from the viral polyprotein, 
respectively (120, 133). Since they are critical for SARS-CoV replication, they are 




The PLpro domain resides within nsp3, which is the largest replicase subunit.  
Nsp3 is a multifunctional, multidomain protein; however, the function of many of the 
domains identified within SARS-CoV nsp3 is not well known. Nevertheless, the 
investigation of the papain-like protease of SARS-CoV has illustrated the multi-
functionality of coronaviral PLPs. Several reports have demonstrated that the PLpro 
domain of nsp3 functions not only as a viral protease, but also possesses deubiquitinating 
(DUB) and deISGylating activities (135, 138-139, 199, 201).  The host cell uses both Ub 
and ISG15 as unique signaling components to promote the antiviral innate immune 
responses during viral infection. The fact that SARS-CoV PLpro can cleave and disrupt 
important host cell innate immune elements illustrates the multifunctional nature of this 
protease and suggests that it is a major virulence factor.  
 
SARS-CoV generally does not induce type I IFN in infected cells in culture, 
which suggests that SARS-CoV evades or suppresses the induction of type I IFN (162).  
We previously demonstrated that PLpro domain of SARS-CoV nsp3 is a potent IFN 
antagonist, which acts to suppress IRF-3-dependent type I IFN induction by interacting 
with IRF-3 and inhibiting its phosphorylation, dimerization, and nuclear translocation 
(186). Furthermore, we showed that the inhibition of the IFN response was independent 
of the protease activity.  Although the mechanisms of actions are different, other groups 
have demonstrated a similar phenomenon that SARS-CoV PLpro can inhibit IRF-3-
dependent type I IFN induction (194).  Most of the in-vitro studies examining the 
functional role of the PLpro domain have mainly used truncated nsp3 PLpro domain 
constructs. On the contrary, Wathelet et al transiently expressed SARS-CoV full-length 
nsp3 protein in HEK293T cells and demonstrated that nsp3 expression could inhibit 
virus-induced type I IFN induction (191).  However, the authors did not dissect the 
antagonistic properties of nsp3 and determine what domain was responsible for this 
ability.  To our knowledge, it has not been shown whether expression of SARS-CoV 
PLpro impacts IRF-3 signaling when stably expressed in the context of the full-length 
nsp3 protein, which is the case in virus-infected cells.   
 
The objective of this study was to investigate the effects of SARS-nsp3 
expression on the IRF-3 innate immune signaling pathway. Examining the function of 
PLpro on induction of the type I IFN responses to viruses, in the context of the full-length 
nsp3 protein, is essential to the understanding of SARS pathogenesis. In this present 
study, I provide evidence that SARS-nsp3 contributes to SARS-CoV antagonism of IRF-










Inducible Expression of SARS-CoV Nsp3 Inhibits IRF-3-Dependent Antiviral Gene 
Responses. 
 
To guard against virus infection, mammalian cells employ a complex antiviral 
defense program characterized by the rapid induction of immediate early antiviral genes 
such as (IFN-α/β), ISG15 and ISG56 (160). We have previously reported that the PLpro 
domain inhibits the activation of the IFN-β promoter following engagement of TLR3 or 
RIG-I pathways (186). As mentioned above, the PLpro domain is a catalytically active 
domain within nsp3.  Therefore, I investigated whether SARS-nsp3 behaves in a similar 
fashion and can regulate the induction of IRF-3-dependent type I IFN responses.  To 
examine the effect of SARS-nsp3 in the antagonism of type I IFN responses, I used the 
Flp-In-T-Rex expression system to generate HeLa cells that stably express SARS-nsp3, 
in a tetracycline-regulated fashion named HeLa-Fit-ScoV-nsp3. The SARS-nsp3 protein 
is tagged with a 2xHA-epitope at the N-terminus, to facilitate its detection. This system is 
unique as it allows for the generation of stable, inducible cell lines using site-specific 
recombination and integration mediated by Saccharomyces cerevisiae-derived Flp 
recombinase (229), thus obliterating the sometimes difficult transient expression 
dynamics, where the efficiency of transfection decreases with very large expression 
plasmids. Furthermore, some cell lines may be refractory to transfection.  
 
HeLa-Fit-ScoV-nsp3 cells in the absence or presence of Tet, to repress or induce 
expression of SARS-nsp3, were cotransfected with a plasmid expressing the firefly 
luciferase reporter gene under control of the human IFNβ promoter and a constitutively 
expressed Renilla luciferase-encoding plasmid. The Renilla luciferase activity serves as 
an internal control to normalize the transfection efficiency of the IFNβ reporter plasmid. 
After induction of the IFN pathway by SeV infection, a known potent inducer of IRF-3-
dependent gene expression via RIG-I pathway, firefly luciferase activity was measured 
and normalized relative to Renilla luciferase expression. As expected, the IFN-β 
promoter is activated through TLR3 (data not shown) or RIG-I pathways (Figure 4.1); 
however, in the presence of SARS-nsp3, activation of the virally induced IFNβ promoter 
is significantly reduced Figure 4.1. SARS-nsp3 expression did not affect SeV infection, 
since SeV protein expression detected shows comparable levels in Tet-induced and 
uninduced HeLa-Fit-ScoV-nsp3 cells.These data suggest that SARS-nsp3 inhibits IRF-3-
dependent transcription of IFN-β. I therefore investigated the ability of SARS-nsp3 to 
prevent the induction of an additional well-characterized IRF-3-dependent target gene, 
ISG56, and determined if this ability is dependent on the PLpro domain.  
 
Inverse PCR mutagenesis was employed to generate a SARS-nsp3 PLpro domain 
deletion construct. Using the strategy that I implemented to generate the HeLa-Fit-ScoV-
nsp3 cell line, I created HeLa cells that stably express HA-SARS-nsp3-delPLpro, in a 
tetracycline-regulated fashion designated HeLa-Fit-ScoV-nsp3-delPLpro. These cells 
were used in combination with HeLa-Fit-ScoV-nsp3 cells to evaluate SARS-nsp3’s 





Figure 4.1. Inducible expression of SARS-CoV nsp3 inhibits virus-dependent 
activation of the IFNβ promoter. 
 
Activation of IFNβ promotor, HeLa-Fit-ScoV-nsp3 cells were grown for 48 h in the 
absence (-Tet) (blue bars) or presence (+Tet) (red bars) of 2ug/ml Tet treatment to repress 
or de-repress HA-SARS-nsp3 expression (Performed in triplicates). Subsequently, cells 
were co-transfected with pIFNβ-luc (80ng/well) and pRL-TK (20ng/well). Cells were 
then mock infected or infected with 100 HAU of SeV for 16 hrs prior to cell lysis and 
assayed for relative luciferase activity as a readout of IFN-β activity. The error bars 





 role in the antagonism of IRF-3-dependent type I IFN responses in the context of the 
full-length nsp3 protein. In the absence of tetracycline in the culture medium, both cell 
lines exhibited no detectable exogenous protein expression Figure 4.2 (odd numbered 
lanes). 
 
 However, upon the addition of tetracycline into the culture medium, both cell 
lines demonstrated robust expression levels of HA-SARS-nsp3 and HA-SARS-nsp3-
delPLpro respectively Figure 4.2 (even- numbered lanes). This finding suggests that 
expression of the wild-type (wt) and delPLpro mutant of SARS-nsp3 is tightly regulated 
by tetracycline and that their expression levels are comparable. Consistent with data 
obtained from the IFN-β promoter assay Figure 4.1, I found that inducible expression of 
wt HA-SARS-nsp3 greatly inhibited the SeV induction of endogenous ISG56 expression, 
but in the presence of HA-SARS-nsp3-delPLpro mutant, this ability is lost Figure 4.2.  
 
To further verify my observations, I used Image J software to quantify ISG56 
expression. The value of ISG56 expression is a measure of the relative intensity of each 
band compared to the standard (control cells -Tet), having a relative density value of 100. 
In the presence of HA-SARS-nsp3, ISG56 band intensity was decreased by 52%, 
illustrating the profound inhibitory effect that HA-SARS-nsp3 has on IRF-3-dependent 
gene expression Figure 4.2 (left panel). Interestingly, there is a slight increase in ISG56 
band intensity in the presence of HA-SARS-nsp3-delPLpro Figure 4.2 (right panel), 
suggesting that SARS-nsp3 PLpro domain plays a key role in SARS-CoV escape from 
host innate immune responses. These findings demonstrate that SARS-nsp3 has the 
ability to efficiently disrupt virus-induced expression of IRF-3-dependent antiviral genes 
and that this ability is dependent on the PLpro domain. 
 
 
SARS-CoV Nsp3 Does Not Inhibit the JAK/STAT1 Pathway 
 
Our data show that HA-SARS-nsp3 can inhibit the induction of type I IFN 
responses; therefore, I also examined whether HA-SARS-nsp3 could inhibit type I IFN 
signaling downstream of the IFN receptors.  The JAK/STAT pathway is a well-
established IFN-dependent pathway that is triggered by the secretion of type I IFNs. 
Activation of this pathway consists of the nuclear translocation and initiation of gene 
transcription by STATs, which have been activated in response to JAK-mediated 
phosphorylation (160). To determine the effects that HA-SARS-nsp3 has on IFN 
signaling, I examined the IFN-induced phosphorylation of Stat1, a key molecule that is 
indispensable for the JAK/STAT pathway activity. HeLa-Fit-ScoV-nsp3 cells in the 
absence or presence of Tet, to repress or induce expression of HA-SARS-nsp3, were 
treated with IFN-α for 1 hr.  Treatment with IFN-α induced the phosphorylation of 
STAT1; however, in the presence of HA-SARS-nsp3, pSTAT1 protein expression was 
not inhibited Figure 4.3. These data suggest that SARS-nsp3 does not block IFN-






Figure 4.2. SARS-nsp3 ability to inhibit virus-induced ISG56 expression is 
dependent on the PLpro domain. 
 
Immunoblot analysis of HA-SARS-nsp3, HA-SARS-nsp3-delPLP, Actin, and ISG56 
expression in HeLa-Fit-ScoV-nsp3 and HeLa-Fit-ScoV-nsp3-delPLP cells that were 
mock infected (lanes 1:2 and 5:6) or challenged with SeV (100HAU; lanes 3:4 and 7:8) 
for 16 hrs in the absence ( -Tet, odd-numbered lanes) or presence (+Tet, even-numbered 
lanes) of 2ug/mL of Tet treatment for HA-SARS-nsp3 and HA-SARS-nsp3-delPLP 










Figure 4.3. Inducible expression of SARS-Nsp3 does not inhibit IFN-induced 
Stat1 Phosphorylation. 
 
Immunoblot analysis of HA-SARS-nsp3, Actin, and pStat1 expression in HeLa-Fit-
ScoV-nsp3 cells that were mock treated (lanes 1 and 2) or treated with IFNα (200 units; 
lanes 3 and 4) for 1 hour and (lanes 5 and 6) for 2 hrs in the absence (odd-numbered 
lanes) or presence (even-numbered lanes) of 2ug/mL of Tet treatment for HA-SARS-




SARS-CoV Nsp3 Has the Ability to Compromise the TLR3 and RIG-I Stimulated 
Antiviral Response. 
  
Vesicular Stomatitis Virus (VSV) replication is known to be highly sensitive to 
the antiviral action of type I IFNs; thus, it is a useful tool to assay for antiviral activities. 
To investigate SARS-nsp3-mediated inhibition of type I IFN induction, I studied the 
effects of HA-SARS-nsp3 expression on the establishment of an antiviral state induced 
by TLR3 and RIG-I ligands.  It is well known that the TLR3 signaling pathway can be 
stimulated by a synthetic dsRNA analog, polyriboinosinic:polyribocytidylic acid (poly 
I:C) (243). As with viral dsRNAs, engagement of TLR3 with poly (I-C) activates the 
TRIF-dependent pathway, culminating in the induction of type I IFNs, proinflammatory 
cytokines, and chemokines, mediated by NF-κB and IRF-3 activation (222). Therefore, 
HeLa-Fit-ScoV-nsp3 cells were left uninduced or induced with Tet, to repress or turn on 
expression of HA-SARS-nsp3. 48 hrs later cells were either mock treated or treated with 
poly (I-C) in the culture medium, to confer an antiviral state. Afterwards, cells were 
either mock infected or infected with an engineered firefly luciferase reporter-expressing, 
recombinant strain of vesicular stomatitis virus (VSV-Luc). Infected cells express the 
firefly luciferase reporter protein; thus, measurement of firefly luciferase activity is a 
readout for VSV replication.  In the absence or presence of Tet, VSV-Luc replicated to 
similar efficiencies in mock-treated HeLa-Fit-ScoV-nsp3 cells, as determined by the 
VSV-encoded luciferase activity Figure 4.4A. Stimulation by poly (I-C) in the media 
produced an antiviral state in HeLa-Fit-ScoV-nsp3 cells in the absence of Tet, resulting in 
a significant reduction of VSV-luc replication, when compared to unstimulated cells 
Figure 4.4A. However, in the presence of Tet (HA-SARS-nsp3 expression induced), the 
poly (I-C)-induced antiviral state was compromised Figure 4.4A, suggesting that SARS-
nsp3 impairs the poly (I-C)-established antiviral state via TLR3. 
 
Using tranfection of a hepatitis C virus (HCV) RNA Replicon RNA, a RIG-I 
ligand, I investigated the ability of SARS nsp3 to disrupt the RIG-I-mediated induction of 
the antiviral state. Stimulation with the HCV RNA replicon induces an antiviral state in 
HeLa-Fit-ScoV-nsp3 cells in the absence of Tet, resulting in a significant reduction of 
VSV-luc replication, when compared to unstimulated cells Figure 4.4B. However, in the 
presence of SARS-nsp3, the RIG-I-induced antiviral state is compromised, as 
demonstrated by the significant increase in VSV replication when compared to control 
cells Figure 4.4B. To further prove the PLpro domain is responsible for SARS-nsp3-
mediated IFN antagonistic ability, I examined if inducible expression of SARS nsp3-
delPLpro mutant had the ability to disrupt the poly (I-C)-induced antiviral state.  While 
wt SARS nsp3 maintains the ability to significantly compromise the poly (I-C)-induced 
antiviral state; SARS nsp3-delPLpro lost such ability. 
  
VSV contains a ribonucleoprotein (RNP) complex that consists of the viral 
genome RNA enwrapped by the nucleoprotein (NP), which serves as a template for 
mRNA transcription as well as genome replication (1).  Thus, to further investigate 
SARS-nsp3 inhibition of IFN induction, I tested the effects of SARS-nsp3 on VSV NP 
expression. The VSV NP is expressed robustly in the absence or presence of SARS-nsp3 





Figure 4.4. Inducible expression of SARS-nsp3 compromises TLR3 and RIG-I 
mediated antiviral state. 
 
(A) Cells grown in the absence (-Tet) or presence (Tet+) of 2ug/ml of Tet treatment for 
inducible HA-SARS-nsp3 expression were mock stimulated or stimulated with poly (I-C)  
(25ug/mL), followed by infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, 
cells were lysed for firefly luciferase assay. (B) HeLa-Fit-ScoV-nsp3 cells grown in the 
absence (-Tet) or presence (Tet+) of 2ug/ml of Tet treatment for inducible HA-SARS-
nsp3 expression were mock transfected or transfected with HCV replicon RNA 
(2ug/mL), followed by infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, cells 
were lysed for firefly luciferase assay. (C) Cells grown in the absence (-Tet) or presence 
(Tet+) of 2ug/ml of Tet treatment for inducible HA-SARS-nsp3 and HA-SARS-nsp3-
delPLP expression were mock stimulated or stimulated with poly (I-C)  (25ug/mL), 
followed by infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, cells were lysed 









Figure 4.5. Inducible expression of SARS-nsp3 compromises RIG-I mediated 
antiviral state. 
 
Immunoblot analysis of VSV-NP and Actin expression in HeLa-Fit-ScoV-nsp3 cells. 
Cells grown in the absence (-Tet) or presence (Tet+) of 2µg/ml of Tet treatment. Cells 
were mock transfected or transfected with HCV replicon RNA (2µg/mL), followed by 
infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, cells were lysed for 





Tet, VSV NP expression is greatly diminished Figure 4.5 (lane 4), when compared to 
unstimulated cells Figure 4.5 (lane 3), suggesting that a RIG-I-mediated antiviral state is 
produced.  In comparison, upon turning on HA-SARS-nsp3 expression, VSV NP 
expression is increased Figure 4.5 (lane 8) when compared to control cells, suggesting 
that SARS nsp3 interferes with RIG-I- stimulated antiviral responses, permitting an 
increase in VSV replication.  These findings further prove that SARS-nsp3 has the ability 
to compromise the TLR3- and RIG I-mediated antiviral response, and that this ability is 
mediated by the PLpro domain. 
 
 
SARS-CoV Nsp3 Level of Blockade 
 
IRF-3 plays a pivotal role in the transcriptional regulation of the IFN-β promoter 
and subsequent ISG expression (220, 242). To further establish which step of the IRF-3 
signaling pathway leading to IRF-3 activation is targeted by SARS-nsp3, I determined 
the effect of HA-SARS-nsp3 on the expression of ISG56, following overexpression of 
signaling proteins known to participate in RIG-I/MDA5 and TLR3 pathways upstream of 
IRF-3. I found that HA-SARS-nsp3 strongly diminished the expression of ISG56 by 
overexpression of TBK1 or IKKε Figure 4.6A. In contrast, SARS-nsp3 expression had 
no effect on ISG56 expression in cells overexpressing the constitutively active, phospho-
mimetic IRF-3 mutant, IRF-3-5D Figure 4.6A.  To confirm the observations presented 
above, image J was used to quantify the intensity of ISG56 bands. The intensity values of 
ISG56 bands for HeLa-Fit-ScoV-nsp3 cells in the absence of Tet were set to 100 Figure 
4.6A (odd-numbered lanes), and the values for ISG56 bands in the presence of Tet are 
shown relative to those in the absence of Tet Figure 4.6A (even-numbered lanes).  In 
HeLa-Fit-ScoV-nsp3 cells overexpressing the empty vector, ISG56 band intensity in the 
presence of SARS-nsp3 is decreased by 97% as compared with –Tet cells (no detectable 
nsp3 expression), thus demonstrating the ability of SARS-nsp3 to inhibit IRF-3-
dependent ISG56 expression.  
 
Overexpression of the kinases should constitutively drive up IRF-3 activation and 
subsequent ISG56 expression; however, in the presence of SARS-nsp3, ISG56 band 
intensity is decreased by 67% and 82% respectively Figure 4.6A (lane 6 and 8). In 
contrast, in HeLa-Fit-ScoV-nsp3 cells overexpressing IRF-3-5D, ISG56 band intensity 
increased in the presence of SARS-nsp3 Figure 4.6A (lane 10), suggesting that at this 
level SARS-nsp3’s ability to impair the host innate immune responses is lost. The ability 
of SARS-nsp3 to inhibit TBK1- and IKKε-dependent responses indicates that SARS-
nsp3 acts downstreaml of these signaling molecules to prevent IRF-3 activation.  In 
contrast, SARS-nsp3 was unable to inhibit ISG56 expression by overexpression of IRF-3-
5D, suggesting that SARS-nsp3 functions to prevent the activation of IRF-3, but is unable 
to disrupt IRF-3 function once it is activated by phosphorylation. Therefore, I conclude 
from these experiments that HA-SARS-nsp3 disrupts IRF-3-mediated signaling by acting 
at a level that is downstream of the IRF-3 kinases and upstream of phosphorylated IRF-3. 
 
The active site of SARS-CoV PLpro consists of a canonical Cys1651-His1812-





Figure 4.6. SARS-nsp3 level of blockade dependent on its protease activity. 
 
A) Immunoblot analysis of HA-SARS-NSP3, and ISG56 expression in HeLa-Fit-ScoV-
nsp3 cells grown in the absence (-Tet odd-numbered lanes) or presence (Tet+ even-
numbered lanes) of 2ug/ml f of Tet treatment for FLG-SARS-nsp3 expression cells that 
were transiently transfected with various signaling molecules within the TLR3 and RIG-
1/MDA5 pathways above and below the level of IRF-3; SeV-infected cells (lane 3 and 4) 
serve as a positive control of the SARS-nsp3 blockade of ISG expression. (B) 
Immunoblot analysis of HA-SARS-nsp3, and pIRF3 expression in HeLa-Fit-ScoV-nsp3 
and HeLa-Fit-ScoV-nsp3-C1651A cells grown in the absence (-Tet odd-numbered lanes) 
or presence (Tet+ even-numbered lanes) of 2ug/ml f of Tet treatment for HA-SARS-nsp3 
and HA-SARS-nsp3-C1651A expression cells that were mock infected (lanes 1:2 and 
5:6) or infected with SeV (100HAU; lanes 3:4 and 7:8) for 16 hrs. (C) Activation of IFNβ 
promotor, HeLa-Fit-ScoV-nsp3 and HeLa-Fit-ScoV-nsp3-C1651A cells were grown for 
48 h in the absence (-Tet) (blue bars) or presence (+Tet) (red bars) of 2ug/ml Tet 
treatment to repress or de-repress FLG-SARS-nsp3 or FLG-SARS-nsp3-C1651A 
expression Subsequently, cells were co-transfected with pIFNβ-luc (80ng/well) and pRL-
TK (20ng/well). Cells were then mock infected or infected with 100 HAU of SeV for 16 
hrs prior to cell lysis and assayed for relative luciferase activity as a readout of IFN-β 






protease activity of the PLpro (135).  Next, I determined whether the inhibition of IRF-3 
activation by SARS-nsp3 is dependent on its protease activity. I conducted western blot 
analysis, determining the ability of SARS-nsp3 and a protease-deficient SARS nsp3 
mutant (C1651A) to inhibit virus-induced IRF-3 phosphorylation. I found that when 
SARS-nsp3 was expressed, virus-induced phosphorylated IRF3 was reduced; however, in 
the presence of the catalytic mutant SARS-nsp3-C1651A, there was no observable 
reduction in phosphorylated IRF-3 expression Figure 4.6B.  Quantification of the band 
intensity of pIRF3 further supported the results observed. In the presence of SARS-nsp3, 
pIRF3 band intensity decreased significantly by 64% Figure 4.6B (lane 4), yet in the 
presence of the SARS-nsp3 mutant lacking catalytical activity, pIRF3 band intensity was 
increased by 22%. Furthermore, SARS-nsp3 catalytic mutant is unable to inhibit the 
activation of the IFN-β promoter Figure 4.6C, suggesting that SARS-nsp3 may 
proteolytically cleave cellular proteins in this pathway to interfere with IRF-3 activation, 
thus inhibiting the expression of phosphorylated IRF-3. Alternatively, mutation of the 
C1651 residue in SARS-nsp3 PLpro domain may alter the overall structure of the nsp3 




SARS-Nsp3 Mechanism of Action 
 
It is well established that the TLR3 and RIG-I signaling cascades that elicit IFN-β 
gene induction converge at the 
phosphorylation and activation of IRF-3 (158). We have previously shown that SARS 
PLpro domain inhibits TLR3- and RIG-I-mediated IRF-3-dependent IFN-β induction by 
inhibiting IRF-3 phosphorylation, dimerization, and nuclear translocation (186). 
Additionally, we previously showed a physical interaction of the PLpro with IRF-3, in 
coimmunoprecipitation assays (186). Later studies have also associated the ability of 
CoV PLPs to inhibit type I IFN induction with their ability to antagonize STING, an 
important scaffolding molecule required for the activation of IRF-3, and this ability is 
mediated by catalytic-dependent and catalytic-independent activities (217-218).  Despite 
the advances in understanding the mechanism by which SARS-CoV PLpro inhibits IRF-
3-dependent signaling, evidence suggests that SARS PLpro interferes with the host innate 
immune responses by acting at a level that is downstream of TBK1 and IKK  and in 
proximity to IRF-3. This evidence encouraged us to characterize potential mechanisms of 
SARS-nsp3 inhibition on IRF-3-dependent type I IFN induction. RIOK3 has been 
described as an essential novel adaptor protein required for the cytosolic nucleic-acid-
induced type I IFN response (244). Furthermore, RIOK3 functions downstream of TBK1 
and upstream of IRF-3 activation, making it a potential target of nsp3.  
 
To determine if SARS-nsp3 interacts with RIOK3 to interfere with IRF-3 
activation, HeLa-Fit-HA-ScoV-nsp3 cells repressed or induced for SARS-nsp3 
expression were transfected with a Flag-tagged RIOK3 construct.  After 48 hours of 
transfection, the protein complexes were extracted and subjected to immunoprecipitation 
analysis. Cell lysates were assayed for both HA-tagged SARS-nsp3 and Flag-tagged 





Figure 4.7. SARS-nsp3 does not associate with RIOK3. 
 
(A) Cell lysates were subjected to immunoprecipitation (IP) with a mouse anti-HA and 
anti-FLG antibody, followed by immunoblot analysis of HA-SARS-nsp3, and RIOK3-
FLG. Data shown are representative of two independently conducted experiments. (B) 
HeLa-Fit-ScoV-nsp3 cells grown in the absence (-Tet odd-numbered lanes) or presence 
(Tet+ even-numbered lanes) of 2ug/ml f of Tet treatment for HA-SARS-NSP3 expression 
were transiently transfected with RIOK3-FLG plasmid for 48 hrs. Expression of HA-






experiments using anti-Flag or anti-HA antibodies revealed that SARS-nsp3 does not 
form a complex with RIOK3 Figure 4.7A. It has been reported that the DEAD-box  
helicase DDX3 is also a crucial component in the TBK1/IKK𝜀-mediated activation of 
IRFs and ultimately the induction of type I IFNs (245-247).  Most importantly, DDX3 is 
an important target for viruses to inhibit the induction of the antiviral innate response. For 
example, Hepatitis B virus polymerase functions to inhibit PRR-induced type I IFN 
induction by disrupting DDX3 and TBK1/IKKe complex (248). Likewise, DDX3 was 
identified as a host target of VACV protein, K7, which can inhibit SeV-induced IFN-β 
gene induction by inhibiting TBK1/IKKε-mediated IRF-3 activation (246). As with 
RIOK3, although cell lysates revealed robust expression of endogenous DDX3, following 
Co-IP experiments, no interaction was observed between HA-SARS-nsp3 and DDX3 





The type I IFN (IFN-α/β) response is a crucial early antiviral defense mechanism 
utilized by the host to combat invading viral pathogens.  Type I IFNs function to establish 
an antiviral state within infected and neighboring cells. IFN-β and -α1 gene expression is 
mediated by the transcription factors IRF-3, NF-κB, and AP-1.  Once translated and 
secreted, IFN-β and -α1 bind to their cognate cell surface receptors in an autocrine and 
paracrine fashion. This induces the JAK/STAT signaling pathway, which induces an 
extensive range of interferon-stimulated genes (159,242-243). IRF-3 is also an essential 
regulator of a subset of pro-inflammatory genes such as RANTES and CXCL10, and can 
directly mediate the transcription of certain ISGs with ISRE sites including ISG15 and 
ISG56 (156). Viruses must battle these immune responses to propagate successfully; as a 
result, many viruses encode proteins that interfere with the initial induction of type I 
IFNs, blocking JAK/STAT signaling or inhibiting the antiviral state at a later step.   
 
The initial observation that SARS-CoV induces a poor IFN response led to the 
assumption that the genome encodes antagonists of the IFN system. SARS-CoV has 
created a number of strategies to inhibit type I IFN production. We have shown 
previously that the PLpro domain contained within nsp3 is a potent IFN antagonist (186). 
The PLpro domain was shown to inhibit IFN-β by blocking IRF-3 phosphorylation, 
dimerization and nuclear translocation (186).  Subsequent studies have also shown that 
the PLpro domain blocks IRF-3-mediated IFN induction by diverse mechanisms (194).  
However, the PLpro domain is contained within nsp3, a 213 kDa membrane-associated 
replicase product. To understand fully the pathogenesis of SARS-CoV infection, studies 
are needed to elucidate the mechanisms by which SARS-nsp3 interacts with its host and 
subverts the host antiviral response. A detailed understanding of this interaction in the 
context of the full-length nsp3 protein may yield important information that informs 
development of effective antiviral therapeutics that can be used to attenuate highly 
pathogenic coronaviruses’ replication and pathogenesis.  
 
In the present study, I demonstrate that expression of SARS CoV full-length nsp3 
protein can inhibit IRF-3-mediated antiviral defenses.  In particular, inducible expression 
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of nsp3 was shown to block the activation of virus-induced IFN-β promoter Figure 4.1 
and ISG56 expression Figure 4.2A.  SARS-CoV replication requires the proteolytic 
processing of SARS-CoV replicase polyprotein into individual nsp proteins by two 
virally encoded cysteine proteases, 3CLpro and the PLpro.  Using an autoproteolytic 
mechanism, the PLpro is responsible for the proteolytic cleavage of the amino terminal 
end of the viral polyprotein, resulting in the release of nsp1, nsp2, and nsp3 (120, 134). 
SARS-CoV proteolytic process requires an active site containing a classical catalytic 
triad composed of amino acids Cys1651, His1812, and D1826 (120, 134).  Interestingly, I 
observed that the SARS-nsp3 C1651A protease mutant completely lost the ability to 
block expression of pIRF3, suggesting that this residue is indispensable for SARS-nsp3-
mediated inhibition of IRF-3 activation Figure 4.6B. It is possible that this specific 
mutation of the catalytic site may alter the conformation of the protein, thus affecting the 
substrate binding event that drives the cysteine protease catalytic mechanism.  
 
Although the evidence presented above suggests a protease-dependent mechanism 
for type I IFN antagonism, it is important to consider that the DUB/delSGylation activity 
of SARS nsp3 PLpro domain which may contribute to regulation of innate immunity is 
dependent on the same active site.  Therefore, I cannot exclude the possibility that SARS-
nsp3 may use the DUB/delSGylation activity to inhibit IRF-3 activation. Furthermore, it 
is also possible that the C1651A mutation may alter the overall folding of the nsp3 
protein, disrupting the interaction of nsp3 with potential signaling proteins in the IRF-3 
activation pathway it targets, including iRF-3 itself. Thus, to better understand the role, if 
any, of the catalytic activity in facilitating SARS-nsp3 PLpro inhibition of IRF-3 
activation, it is essential to examine additional mutations in the PLpro domain, such as 
the other two catalytic sites, in the context of the full-length SARS-nsp3 protein.  
Nonetheless, we demonstrated that the ability of SARS-CoV nsp3 to antagonize IRF-3-
mediated gene expression is dependent on the PLpro domain Figure 4.2.   
 
Activation of the type I IFN system results in the stimulation of a signal 
transduction cascade that induces hundreds of ISGs, producing an antiviral state in host 
cells and stimulates the adaptive immune responses (249).  VSV is highly sensitive to 
IFNs, and the presence of type I IFNs blocks VSV replication, as seen when stimulated 
with TLR3 and RIG-I ligands to induce an antiviral state; however, this effect was 
partially reversed by expression of SARS-nsp3 Figure 4.4A and Figure 4.4B. In 
contrast, SARS-nsp3-delPLpro mutant lost the ability to compromise the establishment of 
an antiviral state Figure 4.4C, demonstrating that SARS-nsp3 functions as a negative 
regulator of TLR3- and RIG-I-mediated induction of the antiviral state, which is 
dependent on the PLpro domain, in a biological assay system.  Interestingly, our previous 
results and data published by others have shown that the PLpro domain has the capacity 
to inhibit IRF-3-dependent gene expression by blocking IRF-3 activation (186,194, 
217,218).  Here, I show that SARS-nsp3 inhibitory effect was bypassed by the expression 
of a phospho-mimetic IRF-3 5D, a constitutively active form of IRF-3, indicating that 
nsp3 interferes with IRF-3-mediated signaling in the vicinity of IRF-3, prior to its 
activation Figure 4.6A. Most recently, Chen et al indicated that SARS-CoV PLpro 
negatively regulates IRF-3- dependent antiviral innate immune responses by targeting the 
IRF-3 scaffolding protein STING (217). In contrast to our observations and those of 
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others, Matthews et al observed that SARS-CoV PLpro can inhibit IRF-3 signaling at a 
step after IRF-3 activation, suggesting another antagonistic strategy of PLpro (250).  It is 
unclear why this effect was not observed by us and other research groups. 
 
The PLpro domain may employ multiple mechanisms to inhibit IRF-3 signaling; 
however, the detailed mechanism by which nsp3 inhibits IRF-3 activation has not been 
described.  In search for SARS-nsp3 interacting molecules, I identified two potential 
cellular targets that function downstream of TBK1/IKKε and in the proximity of IRF-3.  
It is well established that DDX3 is a component of the antiviral innate immune signaling 
pathway leading to type I IFN induction.  DDX3 contributes to the upregulation of type I 
IFNs induction through the formation of a complex with IKKε or TBK1 (245-247). IKKε 
phosphorylation of DDX3 is required for the recruitment of IRF-3 into the complex 
(245). Interestingly, similar to STING, DDX3 functions as a bridging adaptor linking 
IKK-related kinases to IRF-3. A recent study identified RIOK3 as a novel adaptor protein 
that is crucial for IRF-3-mediated antiviral defenses (244). This study demonstrated that 
RIOK3 functions downstream of TBK1 and upstream of IRF-3 activation. Furthermore, 
RIOK3 physically formed a complex with both IRF-3 and TBK1 and is required for the 
interaction between TBK1 and IRF-3 (244).  However, upon our investigation, I found 
that SARS-nsp3 does not interact with RIOK3 Figure 4.7A or DDX3 (data not shown).  
It is possible that the experimental conditions used above do not promote SARS-nsp3 
interaction with DDX3 or RIOK3, or that such interactions may be transient and weak. 
Thus, it is important to further determine the potential interaction of SARS-nsp3 with 
DDX3 and/or RIOK3, and search for other potential targets of SARS-nsp3.  While the 
mechanism of action of nsp3 was undefined in this study, future experiments are 
underway to elucidate the precise mechanism by which SARS-nsp3 inhibits IRF-3-
dependent antiviral innate immune responses.   
 
In conclusion, our investigations have demonstrated that SARS-nsp3 protein is a 
bona-fide interferon antagonist, which acts through PLpro-mediated suppression of IRF-3 
activation. SARS-CoV encodes many antagonists of the host innate immune response, 
including open reading frame 6 (ORF6) protein, nucleocapsid, ORF3b, NSP1, NSP3, and 
the PLpro domain (113, 114,186,191,192,194).  Many of these IFN antagonists have 
evolved different strategies to counteract the IFN system by inhibiting IFN synthesis 
and/or signaling. By rapidly inhibiting type I IFN gene induction, SARS-CoV is able to 
suppress the immediate early antiviral innate immune response, resulting in the 
successful establishment of infection. The existence of multiple IFN antagonists in the 
SARS-CoV genome exemplifies the importance of understanding the biology of virus 
and host interactions. 
 
The multifaceted strategies circumventing the initial host innate immune response 
evolved by SARS-CoV likely support the replication and spread of this virus in different 
cell types and different species. Results from this study demonstrate that SARS-nsp3 is a 
key player in this context, suggesting a critical role for this protein in pathogenesis and 
disease outcome.  This work provides further insight into SARS-CoV antagonism of the 
host innate immune response in a biologically relevant setting. Characterization of 
virulence factors responsible for negatively regulating the IFN response is an essential 
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component in the development of vaccines and therapeutics aimed at disrupting this 
critical aspect of viral pathogenesis.  Future studies should be directed towards 









CHAPTER 5.    DISCUSSION 
 
 
An In-vitro System for Comparative Studies of Human Coronavirus (CoV) 
Nonstructural Protein 3 (Nsp3) 
 
The replication of coronaviruses is a highly orchestrated and complex process. To 
date, coronaviruses contain the largest known RNA genome. Comparable to many other 
positive-sense, single-stranded RNA viruses, coronaviruses’ genomic replication and 
transcription are mediated by a large replication complex that is attached to rearranged 
intracellular host membranes (118). Specifically, coronaviruses induce membrane 
rearrangements called double-membrane vesicles (DMVs), which function as a structure 
for viral genome replication and perhaps offer protection from the host defenses (121-
122).  The important role of coronavirus nsp3 in virus replication has been shown by 
several earlier reports (123,124). Nsp3 has been shown to interact with numerous of other 
viral nonstructural proteins involved in replication and transcription and, as such, may 
serve as a scaffolding protein for the recruitment of these viral non-structural proteins to 
the site of DMVs. Angelini et al demonstrated that the full-length and the C-terminal-
truncated form of nsp3 have membrane disarranging and proliferation abilities. 
Furthermore, working in concert, nsp3, nsp4, and nsp6 have the ability to induce DMVs 
which are similar to those observed in SARS-CoV infected cells (123). 
 
Most importantly, nsp3 houses the coronavirus-encoded papain-like protease 
(PLP), which plays a pivotal role in viral polyprotein processing and replication. All 
human coronaviruses, except SARS-CoV and MERS-CoV, encode two PLPs.  When two 
PLPs are encoded, it is the PLP2 that functions similarly to SARS-CoV PLpro.  The 
PLpro mediates cleavage of the replicase polyproteins 1a and 1ab at 3 specific sites, 
generating 3 mature nonstructural proteins (nsp) (from nsp1–3) (3,120, 259).  It is well 
established that the PLpro domain plays a role in antagonism of the host innate immune 
response. To date, the study of coronaviruses’ PLP domain has been largely based on 
utilizing truncated nsp3 constructs that represent specific domains, yet the way that the 
full-length nsp3 protein contributes to antagonizing the antiviral host response to enable 
successful virus infection is not clearly understood. I attempted to address this demand by 
generating stable cell lines that express, in a tetracycline-regulated fashion, the full-length 
nsp3 protein of human coronaviruses OC43, NL63, MERS-CoV and SARS-CoV, 
respectively. Studies in the full-length nsp3 protein context will lead to a greater 
understanding of the complex organization of SARS CoV viral proteins encoding the 
viral proteases, as well as provide insights to their functional relationships. 
 
In order to study the functional role of coronaviral nsp3 in regulation of the host 
innate immune response, I desired to produce stable cell lines that permits the integration 
of the full-length nsp3 expression construct into the host cell chromosome, cells that 
could be used over many experiments, and with expression that is consistent and 
comparable between experiments. Therefore, I utilized the Flp-In T-Rex-system to create 
stable cell lines expressing coronaviral full-length nsp3 proteins in a tetracycline-
regulated manner Figure 3.3A-E. This system is a very useful tool for functional studies 
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because it allows for site-specific integration and stable expression of a gene of interest 
(GOI), providing single-copy isogenic cell lines. Thus, integration should occur into the 
same genomic locus in every clone. As a result, all clones should be identical 
(Invitrogen). Furthermore, Flp-In expression involves introduction of an Flp 
Recombination Target (FRT) site into the genome of the mammalian cell line of choice. 
Thus, integration is site-specific, occurring at the FRT site (229).  Single-copy site-
specific integration should eliminate the integration of multiple copies of integrants and 
random sites of integration into the genome of the host cell. Thus, this system provides 
comparable protein-expression levels within the same batch of cells. In addition, utilizing 
one of the strongest mammalian promoters and regulatory elements from the tetracycline-
resistance operon for transcription of the GOI should permit highly inducible expression 
of the protein of interest. 
 
Several lines of evidence suggest that this system would be useful for generating 
stable cell lines in which inducible expression levels of the GOI are homogenous, 
permitting the evaluation of the function of different coronaviral nsp3 proteins. However, 
a particular observation demonstrated from IFA staining and Western blot analysis is 
considerable variation in Tet-inducible expression levels among the full-length nsp3 
protein of human coronaviruses OC43, NL63, MERS-CoV and SARS-CoV (data not 
shown). Interestingly, this phenomenon was also observed via transient, ectopic 
expression among the full-length nsp3 proteins Figure 3.4A, where the nsp3s would be 
constitutively expressed from the strong CMV promoter. In contrast, upon the addition of 
tetracycline into the culture medium, HeLa-Fit-ScoV-nsp3 cells demonstrated robust 
expression of SARS-nsp3 Figure 3.5A, and this expression is comparable to HeLa-Fit-
ScoV-nsp3-delPLP cells expressing SARS-nsp3-delPLP Figure 3.5A. I postulate that the 
variation in nsp3 expression levels among HeLa-Fit-OC43-nsp3, HeLa-Fit-NL63-nsp3, 
and HeLa-Fit-MERS-nsp3 stable cells is not attributed to size of nsp3 because SARS-
CoV encodes the largest nsp3, yet HeLa-Fit-ScoV-nsp3 stable cells expressed SARS-
nsp3 most robustly.   
 
It is important to note that, although belonging to the same family of viruses, there 
are differences in the amino acid sequence of each coronaviral nsp3 gene (130). Thus it is 
possible that HCoV-OC43, HCoV-NL63, and MERS-CoV codons are suboptimal for 
expression in mammalian cells, as compared to that of SARS-CoV. It is possible that the 
disproportionate levels of expression may be due to suboptimal efficiencies in the 
transcriptional and/or translational regulation of specific coronaviral nsp3 proteins. 
Further experiments are necessary to address the elements contributing to poor protein 
expression of HCoV-OC43, HCoV-NL-63 and MERS-CoV-nsp3s in mammalian cells.  
This is key to a comprehensive understanding of whether CoVs’ nsp3s may differ in their 
effect on host innate immunity. Interestingly, the data provided in this body of work 
suggest that SARS-CoV nsp3 sequence is optimal for expression in mammalian cells; 
which may explain the rather large number of global SARS cases that spread rapidly in a 
short period of time, highlighting the propensity of SARS-CoV to adapt readily to the 
human host thereby allowing efficient human-to-human transmission. I have generated an 
isogenic Tet-inducible gene-expression model system in HeLa cells that stably express 
SARS-CoV-nsp3 and SARS-CoV-nsp3-delPLP Figure 3.5A.  I have demonstrated that 
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HeLa-Fit-ScoV-nsp3 cells express SARS-CoV nsp3 robustly and that expression is 
comparable to HeLa-Fit-ScoV-nsp3-delPlpro cell line Figure 3.5A. Employing such 
inducible cell lines can be useful for SARS-CoV-nsp3 functional studies, providing 
insight into SARS pathogenesis.   
 
 
SARS CoV Nsp3 Regulates Innate Immune Functions 
 
Viruses are exceptionally diverse and have evolved to infect and cause disease in 
almost all life forms, including humans. Needless to say, viruses can have a devastating 
effect on public’s health. Prime examples are, the Spanish influenza (H1N1) pandemic in 
1918, the transmission of the avian influenza virus (H5N1) to humans, and the sudden 
emergence of two highly pathogenic coronaviruses that causes severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS). Thus, continued 
studies of viral pathogens are necessary (42, 260, 261). Viral pathogenesis is the process 
by which a virus causes disease in its host (1). A fundamental property of viruses is their 
complete dependence on a living host for replication. Therefore, it must be noted that the 
pathogenesis of a given virus is a combination of many multifaceted elements unique to a 
specific virus and its individual host. This intimate relationship defines the nature of the 
disease. A crucial component in understanding viral pathogenesis is defining the 
fundamental mechanisms that determine the pathogenesis of infection between a host 
with mild disease and the host that undergoes severe consequences. Thus, understanding 
viral virulence genes and factors that contribute to disease will aid in the pursuit of 
identifying specific targets for antiviral therapeutic interventions intended to prevent the 
development of severe disease.  
 
Host cells respond to invading viruses by initiating host innate immune responses 
characterized by production type I interferons (IFN-α and β) and establishment of an 
antiviral state (113,154-156, 241). The host innate immune response is a rapid first line of 
defense mechanism against viral pathogens. SARS-CoV evades the innate immune 
response through an intricate combination of virus-host interactions that disrupt 
intracellular signaling pathways and weaken the antiviral actions of IFN. Viral regulation 
of the host innate immune response disrupts the relationship between innate and adaptive 
immunity, providing an environment conducive to SARS-CoV replication and spread. 
One viral protein that is likely a significant virulence factor of SARS-CoV is the PLpro. 
The PLpro domain has been shown to have interferon-antagonistic properties, which 
offer SARS-CoV an advantage in its battle against the host innate immune defenses (186, 
194, 217). This influence is mediated, at least in part by the ability of the PLpro to inhibit 
the activation of IRF-3, a transcription factor required for the induction of IFN-β (159, 
186, 194, 217, 220, 242).  
 
Increasing evidence has shown that the PLpro possesses various IFN-antagonistic 
properties (186, 194, 217, 258); however, little is known about the function of the full-
length nsp3 in disrupting IRF-3-dependent innate immunity. SARS-CoV PLpro is 
contained within nsp3, a 213 kDa membrane multi-domain-associated replicase product 
(3). In order to have a comprehensive understanding of the pathogenesis of SARS-CoV, 
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studies clarifying the mechanisms by which SARS-nsp3 interacts with its host and 
disrupts the host antiviral response are necessary. A detailed understanding of this 
interaction in the context of the full-length nsp3 protein may result in biologically 
relevant knowledge that potentially aid in the development of effective antiviral 
therapeutics, which target highly pathogenic coronaviruses’ replication and mitigate 
pathogenesis.  
 
In this body of work, I tried to determine the molecular mechanism by which 
SARS-nsp3 inhibits the IRF-3-dependent antiviral response. While the detailed 
mechanism by which nsp3 inhibits IRF-3 activation still remains undefined, I have 
provided evidence that the full-length nsp3 protein of SARS-CoV functions as a bona-
fide interferon antagonist, inhibiting IFN synthesis by acting at a level proximal to IRF3 
Figure 4.6A. Furthermore, this ability is mediated by the PLpro domain and perhaps in 
part, the catalytic activity Figure 4.6B.  Future experiments that address the mechanism 
of SARS-nsp3-mediated suppression of IRF-3 activation are essential to delineate the 
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